Folate and iron status in women of childbearing age after bariatric surgery by Cherok, Lori
i 
autismrour 
FOLATE AND IRON STATUS IN WOMEN OF CHILDBEARING AGE AFTER 
BARIATRIC SURGERY 
 
 
 
 
 
 
 
 
by 
Lori E. Cherok 
BS, Pennsylvania State University, 1991 
MS, University of Pittsburgh, 2001 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
the Department of Epidemiology 
the Graduate School of Public Health in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2018 
 
ii 
UNIVERSITY OF PITTSBURGH 
GRADUATE SCHOOL OF PUBLIC HEALTH 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
Lori E. Cherok  
 
 
 
It was defended on 
March 21, 2018 
and approved by 
 
Dissertation Advisor 
Steven H. Belle, PhD, MScHyg, Professor, Department of Epidemiology 
Graduate School of Public Health, University of Pittsburgh 
 
Committee Members 
Lisa M. Bodnar, PhD, MPH, RD, Associate Professor, Department of Epidemiology, 
Graduate School of Public Health, University of Pittsburgh 
 
Anita P. Courcoulas MD, MPH, FACS, Professor of Surgery, Department of Surgery 
School of Medicine, University of Pittsburgh 
 
Wendy C. King, PhD, Associate Professor, Department of Epidemiology 
Graduate School of Public Health, University of Pittsburgh 
 
 
 
 
iii 
`
Copyright © by Lori E. Cherok 
2018 
iv 
 
ABSTRACT 
Women of childbearing age constitute a large proportion of bariatric surgery patients.  Bariatric 
surgery is associated with increased risk of nutritional deficiencies.  Adequate folate and iron 
status is important during pregnancy to ensure healthy infant outcomes.  The primary purpose of 
this research was to determine the association between surgical procedure, Roux-en-Y gastric 
bypass (RYGB) vs. laparoscopic adjustable gastric banding (LAGB), and pre- to one year post-
surgery change in serum folate and serum ferritin (an indicator of iron status) among women of 
childbearing age and to determine the prevalence of postoperative folate and iron deficiencies.  
There were 413 subjects (272 RYGB, 141 LABG) for the folate analyses and 426 subjects (280 
RYGB, 146 LAGB) for the ferritin analyses.  The subjects were a subset of participants from the 
Longitudinal Assessment of Bariatric Surgery study.   
Type of surgery was not significantly associated with change in serum folate.  Among 
women who underwent RYGB, daily/weekly multivitamin use at one-year follow-up and 
daily/weekly multivitamin use at both baseline and one-year follow-up were confounders of the 
relationship between RYGB and change in serum folate.  The prevalence of folate deficiency one 
year after surgery was low, 0.7% after LAGB and 1.1% after RYGB.  For change in serum 
ferritin, there were significant interactions between type of surgery and percent weight change 
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and baseline serum ferritin such that the associations of percent weight change and baseline 
ferritin were more pronounced among women who had undergone RYGB compared to LAGB.   
For women who underwent RYGB, greater percent weight change from baseline was associated 
with greater change in serum ferritin (p<.0001).  The prevalence of iron deficiency was greater 
(p=.04) among women who underwent RYGB than LAGB (21.8% vs. 13.7%).   
This research is relevant to public health because it provides evidence that RYGB 
presents a potential risk to perinatal health due to iron deficiency one year after surgery for 
women who become pregnant.  The folate results should be interpreted with caution due to the 
use of serum folate, an indicator of short-term folate status and intake.  Additional research is 
recommended using red blood cell folate concentration to determine folate status. 
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1.0  INTRODUCTION 
1.1 BACKGROUND 
An estimated 196,000 bariatric surgical procedures are performed each year in the United 
States.1  Prospective studies in the U.S. have reported that approximately 80% of bariatric 
surgery patients are women.2,3  Of these women, approximately 50% are in the childbearing age 
range of 18-45 years.4,5  Prior to bariatric surgery, 30% of women of childbearing age reported 
future pregnancy was important to them and 33% of these women planned to become pregnant 
within two years of surgery.6  In a large prospective cohort study, 45% of women reported 
unprotected intercourse during the first year after bariatric surgery.7 
Having good nutritional status prior to pregnancy is important for healthy infant 
outcomes.8  Two critical nutrients during the periconceptional period are folate and iron.8  One of 
the recognized complications of bariatric surgery is an increased risk for micronutrient 
deficiencies.9,10  The American Association of Clinical Endocrinologists, the Obesity Society, 
and the American Society for Metabolic and Bariatric Surgery recommend women avoid 
becoming pregnant for 12-18 months following bariatric surgery.11  However, some researchers 
recommend that a longer period is needed between surgery and pregnancy to decrease the risk of 
negative infant outcomes.12 
2 
1.1.1 Overview of bariatric surgical procedures 
Bariatric surgical procedures produce weight loss through a number of mechanisms, including 
reducing food intake related to altered levels of gut hormones and gastric volume restriction, 
changing food preferences, and intestinal malabsorption of macronutrients.13,14  The most 
common procedures currently utilized in the U.S. are the sleeve gastrectomy, estimated to 
account for 53.8% of procedures performed, Roux-en-Y gastric bypass, estimated to account for 
23.1% of procedures performed, and laparoscopic adjustable gastric banding, approximately 
5.7% of procedures performed.1  
In the sleeve gastrectomy (SG) (Figure 115), approximately 80% of the stomach is 
surgically removed, leaving a narrow gastric tube which includes the pyloric sphincter.16  This 
surgery promotes weight loss by increasing satiety due to the reduced size of the stomach pouch 
and decreased production of ghrelin, a gastrointestinal hormone that stimulates hunger, resulting 
in restricted food intake.16-18   
 
Figure 1:  Sleeve gastrectomy 
3 
Laparoscopic adjustable gastric banding (LAGB) (Figure 219) is a reversible procedure 
involving the placement of a hollow band around the upper portion of the stomach to create a 
small stomach pouch.16  The size of the pouch can be adjusted by increasing or decreasing the 
amount of saline injected into the band through a subcutaneous port.16  Weight loss results from 
decreased food intake related to increased satiety caused by the small size of the stomach 
pouch.16 
 
Figure 2:  Laparoscopic adjustable gastric banding 
 
For the Roux-en–Y gastric bypass (RYGB) (Figure 320), the first component of the 
surgery is to create a small stomach pouch, with a volume of approximately 30 milliliters, using 
staples.16,21  The second component involves intestinal surgery to reroute the passage of food 
from the gastric pouch directly to a segment of the jejunum bypassing the distal stomach, 
duodenum, and proximal jejunum.16  The altered secretion of gastrointestinal hormones and 
smaller stomach pouch result in increased satiety and limit the amount of food that can be 
consumed at one time.16,22  Weight loss is also achieved by altering the flow of nutrients through 
the proximal intestine, which decreases mixing time of nutrients with gastric acid, bile, and 
4 
pancreatic enzymes, leading to the malabsorption of some macronutrients and thus, calories.22  A 
large prospective study comparing weight change for patients who underwent RYGB versus 
LAGB at three years following surgery reported that RYGB participants lost 31.5% of baseline 
weight compared to only 15.9% for LAGB participants (note: weight change data for participants 
who had undergone SG were not provided).4 
 
 
Figure 3:  Roux-en-Y gastric bypass 
1.1.2 Bariatric surgery and micronutrient deficiencies 
Micronutrient deficiencies are well-known complications of bariatric surgery.9,10,23-26  Patients 
who have undergone bariatric surgery are at risk for deficiencies of vitamin B12, thiamin, folate, 
vitamin C, vitamins A, D, and K, calcium, iron, zinc, and copper.9,10  Some studies report on 
serum ferritin which reflects iron stores in the body and is used as an indicator of early iron 
5 
deficiency.27  The mechanism of action of deficiency varies for each specific micronutrient but 
includes: decreased oral intake due to smaller stomach capacity, increased satiety, food 
intolerances (e.g. meat), and dietary restrictions, frequent vomiting, noncompliance with 
multivitamin (MVI) and minerals supplementation recommendations, and altered nutrient 
absorption due to intestinal bypass or decreased secretion of hydrochloric acid (HCl) or intrinsic 
factor, needed for absorption of iron and vitamin B12, respectively.9,10,22  The risk of 
micronutrient deficiency varies based on the type of surgery, with the surgeries that are the most 
successful in producing weight loss being more likely to result in micronutrient deficiencies.24  
Micronutrient deficiencies are more common after biliopancreatic diversion (BPD) and RYGB 
due to the malabsorptive component of the surgeries.23,25,26   
 Due to the risk of deficiencies, the American Society for Metabolic and Bariatric Surgery 
has provided recommendations for postoperative micronutrient supplementation.23,28  For 
individuals who have undergone LAGB, a MVI with minerals supplement that provides 100% of 
the daily value for at least two-thirds of the nutrients including folate, iron, zinc, and selenium is 
recommended.23  After RYGB, it is recommended to take a MVI with minerals supplement that 
provides 200% of the daily value for at least two-thirds of the nutrients.23  This is often achieved 
by taking two MVI with minerals supplements per day.  It is recommended that individuals who 
have undergone bariatric surgery receive 400-800 µg of folate daily from a MVI with minerals; 
while, women of childbearing age should take 800-1000 µg of folate daily.28   Women who are 
menstruating or have undergone RYGB are recommended to take at least 45-60 mg of elemental 
iron daily as a combination of iron provided by the MVI with minerals supplement and an 
individual supplement; otherwise, 18 mg of iron from a MVI with minerals supplement is 
recommended.28  Individuals who have undergone LAGB or RYGB should take at least 12 mg of 
6 
thiamin daily, 350-500 µg of sublingual or liquid vitamin B12 or 1000 µg of intramuscular 
vitamin B12 monthly, 1200-1500 mg of calcium, and vitamin D supplementation based on serum 
levels.28   
1.1.2.1 Micronutrient deficiencies in adults with obesity  
When examining the prevalence of micronutrient deficiencies resulting from bariatric surgery, it 
is important to acknowledge candidates for bariatric surgery may have preexisting deficiencies.  
While it may seem counterintuitive that individuals with obesity would have micronutrient 
deficiencies, studies have proven otherwise.29-35  Individuals with obesity may consume foods 
high in calories, sugar, and fat but low in micronutrient density.36  In addition, the bioavailability 
of certain micronutrients may be decreased due to altered absorption, distribution, metabolism, 
or excretion processes in individuals with obesity.37  Table 1 provides a summary of prevalence 
data on micronutrient deficiencies for adults with obesity (note: only data for women is included 
in the table).  
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Table 1:  Summary of findings on prevalence of micronutrient deficiency specifically for 
women with obesity  
 
Author, year 
(location) 
Female 
subjects only 
Micronutrients assessed (serum level used to define 
deficiency) 
Prevalence of  
deficiency  
Kimmons, 
200630 
(United States) 
1320 
premenopausal 
women (mean 
age 34.5 years) 
folate (serum folate <3 ng/mL, RBC folate <109 ng/mL)  
vitamin A (<30 µg/dL) 
total carotenoids (NR) 
vitamin B12 (<299 pg/mL) 
vitamin C (<0.4 mg/dL) 
vitamin D (<15 ng/mL) 
vitamin E (NR) 
selenium (<100 µg/L) 
32%, 18% 
2% 
40% 
17% 
35% 
19% 
26% 
6% 
Nicoletti, 
201333 
(Brazil) 
65 women 
(mean age 
specifically for 
women NR) 
folate (<3 ng/mL) 
iron (ferritin <6 ng/mL, serum iron <40 µg/dL) 
vitamin A (<20 µg/dL) 
beta-carotene (<40 µg/100 dL) 
vitamin B12 (<174 pg/mL) 
vitamin C (<0.3 mg/dL) 
copper (<70 µg/dL) 
magnesium (<1.4 mEq/L) 
zinc (<50 µg/dL) 
0% 
0%, 11% 
11% 
0% 
2% 
12% 
0% 
22% 
0% 
Flancbaum, 
200629 
(United States) 
320 women 
(mean age NR) 
iron (ferritin NR, serum iron NR) 
thiamin (NR) 
vitamin B12 (NR) 
vitamin D (NR) 
calcium (NR) 
10%, 42% 
29% 
0% 
68% 
4% 
Ernst, 200935 
(Switzerland) 
165 women, 
(mean age 40 
years) 
 
 
 
 
 
 
Subgroup: 66 
women (mean 
age 40.5 years) 
folate (<4.5 nmol/L equivalent to <1.99 ng/mL) 
iron (serum ferritin <18 pmol/L equivalent to <8 ng/mL) 
vitamin B12 (<133 pmol/L) 
vitamin D (<76 nmol/L) 
magnesium (<0.7 mmol/L) 
phosphate (<0.8 mmol/L) 
zinc (<11 µmol/L) 
 
vitamin A (<0.7 µmol/L) 
thiamin (<933 nmol/L) 
niacin (<65 µmol/L) 
vitamin B6 (<33.2 nmol/L) 
vitamin E (<12 µmol/L) 
copper (<13 µmol/L) 
selenium (<0.9 µmol/L) 
3% 
9% 
19% 
90% 
5% 
7% 
26% 
 
0% 
0% 
6% 
3% 
3% 
0% 
30% 
Abbreviations: RBC: red blood cell; NR: not reported 
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Table 1 (continued): Summary of findings on prevalence of micronutrient deficiency 
specifically for women with obesity  
 
Author, year 
(location) 
Female 
subjects only 
Micronutrients assessed (serum level used to define 
deficiency) 
Prevalence of  
Deficiency  
Schweiger, 
201032 
(Israel) 
83 women 
(mean age 
specifically for 
women NR) 
folate (<5.6 ng/mL) 
iron (ferritin <20 ng/mL, serum iron <60 µg/dL) 
 
26% 
32%, 41% 
Sanchez, 
201634 
(Chile)  
103 women 
(mean age 36 
years) 
 
 
 
 
Subgroup: 66 
subjects (mean 
age NR) 
iron (ferritin<12 µg/L equivalent to <12 ng/mL,  
    serum iron <50 µg/dL, transferrin saturation <16%) 
calcium (<8.5 mg/dL) 
copper (<70 µg/dL) 
phosphorus (<2.5 mg/dL) 
zinc (<60 µg/dL) 
 
folate (<1.5 ng/mL) 
vitamin B12 (<200 pg/mL) 
vitamin D (<20 ng/mL) 
9% 
13%, 15% 
13% 
0% 
2% 
3% 
 
0% 
11% 
46% 
Abbreviations: NR: not reported 
 
 
Using National Health and Nutrition Examination Survey (NHANES) data from 1988-
1994, Kimmons et al.30 determined the prevalence of low micronutrient serum levels by body 
mass index (BMI) category (normal weight, overweight, and obese), age group, and gender.  The 
prevalence of deficiency for premenopausal women with obesity (n=1320) are presented in Table 
1.  In comparison, the prevalence of deficiency for premenopausal women having a normal 
weight based on BMI (n=1980) was 16% in folate based on serum folate and 18% based on RBC 
folate, 17% in vitamin E, 11% in total carotenoids, 20% in vitamin C, 3% in selenium, 1% in 
vitamin A, 8% in vitamin D, and 18% in vitamin B12.  For premenopausal women, increasing 
BMI category was associated with lower serum levels of folate, vitamin E, total carotenoids, 
vitamin C, selenium, and vitamin D (p<.05, linear trend).   Of note, the NHANES data for this 
study were obtained prior to the 1998 initiation of the Food and Drug Administration’s 
mandatory folate fortification program for enriched grains and cereals.  
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The studies listed in Table 1 provide evidence that deficiency of micronutrients, 
including folate and iron, is not uncommon among women with obesity.  The prevalence of 
micronutrient deficiencies in females with obesity ranged from 0% - 32% 30,32-35 for folate, 0% - 
42% 29,32-35 for iron, 35-90% for Vitamin D29,30,34,35, 0-26% for zinc33-35, and 2-19% for vitamin 
B1229,30,33-35.   The subjects in the majority of these studies were candidates for bariatric surgery 
with prevalence of deficiencies determined prior to bariatric surgery.  The biomarker used to 
identify deficiency varied for folate (serum folate or RBC folate) and iron (serum ferritin, serum 
iron, or transferrin saturation).  In addition, the laboratory cutoffs to define deficiencies varied 
among studies, which leads to differences in the prevalence of deficiency.   
It is plausible that some of those with deficiency after bariatric surgery may have had 
preoperative deficiency or a preoperative deficiency that was worsened by the decreased food 
intake and malabsorption caused by bariatric surgery.  In addition, treating deficiencies with 
micronutrient supplementation may affect the postoperative serum levels.  Therefore, 
determining folate and iron status prior to surgery is important context when reporting the 
prevalence of postoperative deficiencies.   
1.1.3 Concerns with pregnancy after bariatric surgery 
Due to rapid weight loss following bariatric surgery and the potential for maternal nutrient 
deficiencies, there is concern for the safety of the fetus among women who become pregnant 
after bariatric surgery.38  Results of studies have been mixed, with earlier case reports (1986-
1996) showing complications such as neural tube defects, anemia, and intrauterine growth 
retardation; while, later larger studies (2004-2010) have not reported an increased risk of 
perinatal complications following bariatric surgery.38,39  Kjaer and Nilas39 postulated that adverse 
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obstetric outcomes may be due to obesity rather than the surgery itself.  A recent matched 
retrospective cohort study by Hammeken et al.40 reported a higher risk of giving birth to small-
for-gestational-age infants and maternal anemia among women who had undergone RYGB 
compared to controls who did not have a history of RYGB.  In another retrospective cohort 
study, Parent et al.12 reported a greater risk of prematurity, neonatal intensive care unit 
admission, and small-for-gestational-age status for infants of mothers who had bariatric surgery 
compared to infants of mothers who did not have prior bariatric surgery.  In addition, the risk of 
infant prematurity, neonatal intensive care admission, and small-for-gestational-age newborns 
was higher for women who gave birth less than two years after surgery compared to women who 
gave birth greater than four years after bariatric surgery.12  
Due to the potential risk to fetal health, the American Association of Clinical 
Endocrinologists, the Obesity Society, and the American Society for Metabolic and Bariatric 
Surgery recommend that women avoid becoming pregnant for 12-18 months following bariatric 
surgery.11  Based on the results of their study, Parent et al.12 suggested that the recommended 
minimum safe interval from bariatric surgery to infant birth should be increased to three years.  
However, in a study by Menke et al.7, 3.5% of women reported trying to conceive during the first 
year following bariatric surgery.  The Committee on Obstetric Practice of the American College 
of Obstetricians and Gynecologists recommends women who have undergone bariatric surgery 
and are pregnant, or are planning to become pregnant, should be evaluated for potential 
deficiencies in iron, folate, vitamin B12, vitamin D, and calcium.41 
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1.1.4 Importance of periconceptional folate status 
Folate, a water-soluble B vitamin, functions in the body as a cosubstrate in many reactions 
involving amino acids and nucleotides, such as in the synthesis and repair of DNA.42  Folate is 
required for the formation and maturation of erythrocytes and white blood cells, the conversion 
of homocysteine to methionine, normal cell division, and embryo and fetal development.42  It has 
long been recognized that inadequate maternal folate status prior to, and early in, pregnancy is 
associated with the development of neural tube defects such as spina bifida.43  Inadequate 
maternal folate status during pregnancy is also associated with higher risk for fetal growth 
retardation, low birth weight, and preterm delivery. 44 
1.1.4.1 Folate deficiency 
Folate deficiency can be caused by a poor quality diet, alcoholism, drug-nutrient interactions, 
and malabsorptive disorders such as celiac disease and Crohn’s disease.45,46  Individuals who 
suffer from alcohol abuse commonly experience negative folate balance or folate deficiency.47  
Alcohol has numerous negative effects on folate status such as decreased intestinal absorption, 
inadequate utilization in the body, and greater urinary excretion.47,48  Individuals with alcoholism 
often have decreased dietary intake of folate due to poor quality diets.47,48  Despite the Food and 
Drug Administration’s mandatory folate fortification program for enriched grains and cereals 
which began in 1998, there are still some populations in the U.S. at risk for inadequate intake of 
folate such as non-Hispanic black women.49    
Food sources of folate and folic acid include green vegetables such as spinach, asparagus, 
and Brussels sprouts, fresh fruit and fruit juice, and fortified cereals, breads, pasta, and rice.50  
Folate is found naturally in foods in polyglutamate forms and also as folic acid, the 
12 
monoglutamate form used in fortification.49,51  The polyglutamate forms must first be hydrolyzed 
by enzymes in the proximal small intestine to the monoglutamate form prior to absorption.  Folic 
acid does not require digestion and is readily absorbed.51  In the body, folate is found in a 
number of active, interconvertible forms.51  Examples of the active forms of folate and metabolic 
functions of each are included in Table 2. 
 
Table 2:  Active forms of folate and metabolic functions  
 
From Gropper/Smith. Advanced Nutrition and Human Metabolism, 6E. © 2013 Brooks/Cole, a part of Cengage, Inc.  
Reproduced by permission. www.cengage.com/permissions  
 
 
The primary methods for determining an individual’s folate status are serum folate or 
RBC folate concentration.52  Characteristics of these tests are presented in Table 3.  Serum folate 
level is an indicator of short-term folate status, while RBC folate concentration reflects more 
long-term folate status.52,53  The decision to use serum folate rather than RBC folate for the study 
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reported here was because RBC folate concentration requires whole blood samples containing 
red blood cells, which were not available from LABS-2 participants.  Other practical 
considerations are that the RBC assay is technically more difficult to perform and is more 
expensive than the serum folate assay.54  Serum folate is also a better measure for individuals 
who have vitamin B12 deficiency.54 
 
Table 3:  Characteristics of laboratory tests used to diagnose folate deficiency 
Test Description Criteria for diagnosing 
folate deficiency  
Comments 
Serum folate Measures the 
amount of folate in 
the blood.55  
<3 ng/mL, females 
and males56,57 
 
 
Serum levels indicate short-term folate 
status and recent dietary intake.51,55  
Elevated serum folate may be caused by 
pernicious anemia.55  
Serum concentrations decrease during 
pregnancy.58 
RBC folate Measures the 
concentration of 
folate in red blood 
cells and is an 
indicator of tissue 
folate.51,55 
<151 ng/mL, females 
and males58 
 
 
RBC folate is an indicator of longer-term 
folate status and decreases after 
approximately 3-4 months of inadequate 
folate intake.51  Vitamin B12 deficiency 
can cause falsely low RBC folate 
concentrations.54,59  Serum concentrations 
decrease during pregnancy.58 
Abbreviation: RBC: red blood cell 
   
Based on 2003-2006 NHANES data, 23% of non-Hispanic black women in the U.S. did 
not meet the Dietary Reference Intake (DRI) estimated average requirement (EAR) for folate 
(including dietary supplement intake) compared to 13% of non-Hispanic white women (p<.003, 
Bonferroni-adjusted).60  Analysis by age group found 17% of 19-30 year-old women and 15% of 
31-50 year-old women in the U.S. had inadequate folate intake even with the use of dietary 
supplements.60  The prevalence of folate deficiency, based on 1999-2010 NHANES data, is 
estimated to be 0.9% among childbearing-age women in the U.S.61    
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1.1.4.2 Bariatric surgery and folate deficiency 
Folate deficiency has been identified in patients after bariatric surgery.10,62-64  Folate deficiency 
can be caused by decreased intake of dietary sources and noncompliance with MVI 
supplementation.23,65,66  Conversion of folate from the 5-methyl tetrahydrofolate form to the 
tetrahydrofolate form requires vitamin B12 to accept the methyl group (Figure 4).51  Deficiency of 
vitamin B12 results in the “methyl-folate trap” and decreased synthesis of tetrahydrofolate.51  
Tetrahydrofolate is the form of folate needed for DNA synthesis.51  The role of vitamin B12 
deficiency is an important consideration since it is a common deficiency after bariatric surgery, 
with a reported prevalence of 62% at 5 years or more after RYGB.67 
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Figure 4:  Role of vitamin B12 in folate metabolism 
From Gropper/Smith. Advanced Nutrition and Human Metabolism, 6E. © 2013 Brooks/Cole, a part of Cengage, Inc.  
Reproduced by permission. www.cengage.com/permissions  
 
1.1.5 Importance of periconceptional iron status 
Iron is a trace element required for many essential body processes.  It is required for the 
formation of hemoglobin in red blood cells and myoglobin in muscle, both of which are needed 
for oxygen transport.68  It is an active component of many enzymes and cytochromes and is 
involved in oxidation and reduction reactions.68  Deficiency of iron results in iron deficiency 
16 
anemia, growth abnormalities, decreased muscle function and exercise tolerance, fatigue, 
epithelial disorders, and impaired cognitive development in children.69  Periconceptional iron 
deficiency increases the risk of iron deficiency anemia in the mother during pregnancy and low 
infant iron stores at birth.70  Maternal anemia early in pregnancy has been associated with greater 
risk of preterm birth71-73 and low birth weight71.  Perinatal iron deficiency interferes with the 
neurodevelopment of the fetus, resulting in difficulties with learning, language skills, emotional 
development, and motor skills.74,75 
1.1.5.1 Iron deficiency 
Iron deficiency can be caused by inadequate intake of dietary sources, acute or chronic blood 
loss, inadequate absorption due to malabsorptive disorders or achlorhydria, and increased iron 
requirements during growth periods.69  Iron deficiency anemia is the final stage of long-term iron 
deficiency.69  Individuals at risk for iron deficiency include women of childbearing age with 
heavy menstrual periods, pregnant women, toddlers and preschool-age children due to increased 
iron requirements, premature infants with decreased iron stores at birth, and individuals with 
gastrointestinal disorders such as celiac disease and inflammatory bowel disease.76,77  A number 
of different laboratory tests can be used to diagnose iron deficiency including serum ferritin, 
serum iron, percent transferrin saturation, and total iron-binding capacity (TIBC).76  
Characteristics of these tests are presented in Table 4.  For this study, serum ferritin was selected 
as the indicator of iron status because it is a sensitive indicator of iron deficiency, an excellent 
indicator of iron stores, and can identify early-stage iron depletion.78-80   
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Table 4:  Characteristics of laboratory tests used to diagnose iron deficiency 
Test Description Criteria for 
diagnosing iron 
deficiency  
Comments 
Serum ferritin Major iron storage 
protein. Serum level is 
an indicator of 
available body iron 
stores.55 
<15 ng/mL, 
adult females79,81 
 
It is a sensitive indicator of iron 
deficiency and can identify early 
negative iron status.79,82 
Ferritin is an positive acute-phase 
reactant protein produced by the liver 
and serum levels increase with 
inflammation.55  
Serum iron Measures the amount of 
ferric iron bound to 
transferrin in the 
blood.83 
<60 µg/dl, adult 
females55 
 
It is a good indicator of the amount of 
iron bound to transferrin.82  It is not a 
sensitive measure of iron deficiency 
and is not useful in diagnosing early 
negative iron balance.82,83 
Percent transferrin 
saturation 
Transferrin is a protein 
that binds and carries 
iron in the blood.55  
This test measures the 
percentage of 
transferrin in the blood 
saturated with iron.55 
<15%, adult 
females55 
Percent transferrin saturation 
decreases with iron deficiency.55 
Transferrin is a negative acute-phase 
reactant protein produced by the liver.  
Serum levels decrease with 
inflammation.55 
Total iron-binding 
capacity (TIBC) 
Measures all iron-
binding protein in the 
blood including 
transferrin.55 
>400 µg/dl, 
females and 
males84 
Serum transferrin levels increase with 
iron deficiency which increases 
TIBC.55  TIBC is an indirect measure 
of serum transferrin and decreases 
with inflammation.55,82  TIBC also 
decreases with liver disease and 
pernicious anemia caused by vitamin 
B12 deficiency.55 TIBC is primarily an 
indicator of liver function.82 
 
 
Based on data from NHANES, the average intake of iron (including iron from 
supplements) for women age 20 years and older is 17.3 mg per day, compared to the RDA of 18 
mg/day.85  Dietary sources of iron include heme iron found in meat, poultry, and fish and non-
heme iron found in legumes, nuts, vegetables, and fortified grains.76  Heme iron is absorbed 
much better than non-heme iron.76  Once heme iron is separated from globin by proteases in the 
stomach and small intestine, it is readily absorbed in the proximal small intestine.84  Non-heme 
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iron must first be hydrolyzed from foods by HCl and proteases produced in the stomach and 
small intestine.84  The freed iron is mostly in the ferric form which is insoluble and must be 
reduced to the ferrous form by HCl in the stomach or reductases produced in the duodenum to be 
absorbed.84  Some of the ferric iron forms and insoluble complex in the alkaline environment of 
the duodenum, which decreases absorption.84  
The prevalence of iron deficiency is estimated to be 13.2% for women aged 20-49 years 
in the U.S.79  Racial differences can be seen with 19.9% of non-Hispanic black females having 
iron deficiency compared to 11.3% of non-Hispanic white females.79 
1.1.5.2 Bariatric surgery and iron deficiency 
Iron deficiency and iron deficiency anemia are common consequences of bariatric 
surgery.10,62,63,86,87  The mechanisms resulting in iron deficiency after bariatric surgery include 
decreased intake of heme iron due to intolerance to meat, hypochlorhydria resulting in decreased 
iron absorption, and decreased intestinal absorption of iron after surgeries that bypass the 
duodenum, such as the RYGB.9,24,65 
1.2 SPECIFIC AIMS AND HYPOTHESES 
Due to the risk of developing folate and iron deficiency after bariatric surgery and the serious 
potential consequences to a fetus caused by these deficiencies, the primary goal of this study is to 
determine the association between bariatric surgery, specifically RYGB and LAGB, and the 
change in serum folate and serum ferritin from before surgery to one year following bariatric 
surgery among women of childbearing age.  While there is research available in the literature on 
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the prevalence of nutrient deficiencies following bariatric surgery, studies often have small 
sample sizes and inconsistent results.  The specific aims of this research are: 
Specific Aim 1:  Conduct a review of the literature regarding the prevalence of 
postoperative deficiencies of folate and iron and their associations between bariatric surgery 
(RYGB, LAGB, and SG).   
Specific Aim 2:  Among women of childbearing age, estimate the prevalence of folate 
and iron deficiencies and examine the distributions of serum folate and ferritin levels prior to, 
and one year following, bariatric surgery.  Determine the change in serum folate and serum 
ferritin levels from baseline to one year following bariatric surgery by type of bariatric surgery - 
RYGB vs. LAGB and determine if the changes in serum folate and serum ferritin differ by type 
of bariatric surgery.  The hypothesis for this aim is women of childbearing age who have 
undergone RYGB surgery will have a larger decrease in serum folate and ferritin from baseline 
to one year following surgery compared to those women who had LAGB surgery. 
Specific Aim 3:  Identify factors associated with change in serum folate and serum 
ferritin levels from baseline to one year after RYGB among women of childbearing age.  The 
hypothesis for this aim is lack of micronutrient supplement use, greater percent weight change, 
and alcohol consumption (folate only) are significantly associated with change in serum folate 
and serum ferritin levels among women of childbearing age who have undergone RYGB.  
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2.0  LITERATURE REVIEW 
2.1 INTRODUCTION 
The objective of this literature review is to describe what has been published regarding the 
association between bariatric surgery and the prevalence of postoperative deficiencies of folate 
and iron.  The literature review focuses on studies that included preoperative and postoperative 
data on folate or iron deficiency for the three most common types of bariatric surgery performed 
in the U.S. – SG, RYGB, and LAGB.  While the population of interest for this study is women of 
childbearing age, there is a paucity of studies conducted solely in women or that provided results 
stratified by sex.  Therefore, the literature review was expanded to include both adult women and 
men. 
2.2 METHODS 
2.2.1 Selection criteria for studies 
The population of interest for the literature search includes adults who had undergone a RYGB, 
LAGB, or SG.  The outcomes of interest are prevalence of folate deficiency, as determined by 
serum folate or RBC folate level, and iron deficiency, as determined by serum ferritin, serum 
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iron, or transferrin saturation.  Inclusion criteria for studies were: (1) age 18 years and older, (2) 
subjects had undergone a RYGB, LAGB, or SG, (3) reported prevalence of folate or iron 
deficiency both preoperatively and postoperatively one to two years following surgery, and (4) at 
least > 40 subjects per surgical group.  Studies were excluded if: (1) no females were included, 
(2) subjects were pregnant at the time of the study, or (3) the surgery was a revision of a previous 
bariatric surgery or a conversion to another bariatric surgery. 
2.2.2 Search strategy 
The OVID database was used to identify studies to be included in the literature review.  The 
search strategy and results are presented in Figure 5.  The final literature search was conducted 
on August 28, 2016.  Articles were limited to English language and human studies only.  No date 
restriction was used.  For research design, the search was limited to clinical trials and 
observational studies.  The following search terms were used to identify the exposure: bariatric 
surgery OR bariatric surger* OR bariatric surgical OR metabolic surger* OR stomach stapling 
OR Roux-en-Y gastric bypass OR gastric bypass OR gastroplasty OR gastric band OR gastric 
banding OR laparoscopic adjustable gastric band OR sleeve gastrectomy OR gastric sleeve OR 
laparoscopic sleeve gastrectomy OR (gastroenterostomy AND obesity).  The search terms used 
for the outcomes were: folate OR folic acid OR ferritin OR iron OR anemia, iron-deficiency OR 
vitamins OR vitamin* OR minerals OR micronutrients OR micronutrient* OR nutrient OR 
nutritional status OR deficiency diseases OR folic acid deficiency OR deficiency OR deficiencies 
OR malnutrition.  The search terms for the exposure and the outcomes were then combined using 
“AND”, which resulted in 114 journal articles after removing duplicates.  After screening the 
abstracts using the inclusion and exclusion criteria, 84 studies were excluded.  An additional 12  
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Figure 5:  Flowchart of the literature review selection process 
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studies were identified by reviewing the reference lists of studies and review articles.  Of the 42 
full articles reviewed, 10 met the inclusion criteria and will be discussed in the literature review.   
2.3 FOLATE AND IRON DEFICIENCY FOLLOWING BARIATRIC SURGERY 
In this section, studies that compared preoperative and postoperative prevalence of folate or iron 
deficiency and met the inclusion/exclusion criteria for this review will be discussed.  A summary 
of the main characteristics and results of the studies is provided in Table 5.   
2.3.1 Folate or iron deficiency following sleeve gastrectomy 
Vage et al.88 evaluated changes in micronutrient levels after LSG in a group of 117 subjects (87 
women, 30 men, mean age 40.3 years).  The prevalence of folate deficiency, based on serum 
folate <5 nmol/L (equivalent to <2.21 ng/mL), was 7.5% at baseline and 8.0% 12 months after 
surgery.  The prevalence of iron deficiency, based on serum ferritin level <25 µg/L (equivalent to 
<25 ng/mL), increased from 11.2% prior to surgery to 19.8% twelve months after LSG (p=.02).  
Mean serum levels were not reported for either micronutrient.  All subjects were advised to take 
one MVI daily.  At the 12-month follow-up, 74% of subjects were taking a MVI, 22% were 
taking a folate supplement, and 3% were taking an iron supplement.  Vage et al.88 reported there 
was no difference in vitamin or mineral status between those subjects who used supplements 
versus those who did not (p-value not reported).    
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2.3.2 Folate or iron deficiency following Roux-en-Y gastric bypass 
2.3.2.1 Folate and iron deficiency 
In a study by Blume et al.89 of 170 patients (136 women, 34 men, mean age 39.5 years), the 
prevalence of folate deficiency, defined as serum folate <2.8 ng/mL, decreased from 6.5% prior 
to RYGB to 1.2% twelve months after surgery (statistical significance not reported) and then 
decreased to 0.6% at 36 months after surgery (p=.009, compared to baseline).  Median serum 
folate levels increased from 8.1 ng/mL at baseline to 13.3 ng/mL at 12 months following surgery 
(p<.05) and increased to 14.6 ng/mL at 36 months (p<.001, compared to baseline level).  
Prevalence of iron deficiency, based on serum ferritin <10 ng/mL, was 5.3% prior to surgery and 
4.1% twelve months following RYGB (statistical significance was not reported).  Median serum 
ferritin levels decreased from 94.5 ng/mL prior to surgery to 69.6 ng/mL at 12 months after 
RYGB.  The researchers reported that 12 months after RYGB, 74.7% of patients were taking a 
combination of individual vitamin or mineral supplements (MVI, iron, folic acid, or vitamin 
B12).  
Dogan et al.90 conducted a clinical trial to compare the prevalence of a number of 
micronutrient deficiencies, including folate and iron, one year following RYGB, between 
subjects randomized to a standard MVI with minerals supplement or a specialized supplement 
designed for RYGB patients.  The standard MVI with minerals supplement provided the RDA 
for folate and iron, whereas, the specialized MVI with minerals supplement provided three times 
the RDA for folate and five times the RDA for iron.  Each supplement was to be taken once per 
day.  There were 148 subjects with 74 per group.  Sample size calculations were performed to 
provide 90% power and 95% sensitivity.  The standard MVI with minerals group had 51 women 
and 23 men with an average age of 43.4 years, and the specialized MVI with minerals group had 
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53 women and 21 men with an average age of 45.3 years.  Prior to surgery, 1.4% of subjects in 
the standard supplement group were folate deficient, based on serum folate <9 nmol/L 
(equivalent to <3.97 ng/mL), compared to 6.8% twelve months after RYGB (statistical 
significance not reported).  Based on serum ferritin <20 µg/L (equivalent to <20 ng/mL), 6.7% of 
subjects in the standard supplement group had iron deficiency at baseline compared to 10.7% 
one year after RYGB (statistical significance not reported).   The prevalence of iron deficiency 
was lower in the specialized supplement group twelve months after RYGB compared to the 
standard supplement group, with 1.3% of subjects in the specialized supplement group having 
iron deficiency (p=.03).  There was no significant difference in the prevalence of folate 
deficiency between the two supplement groups. 
2.3.2.2 Folate deficiency only 
In a study of 58 subjects (46 women, 12 men, mean age 42 years) by Donadelli et al.91, mean 
serum folate levels increased from 7.7 ng/mL at baseline to 14.1 ng/mL one year following 
RYGB (p<.05).  The prevalence of folate deficiency, defined as serum folate <3 ng/mL, was 
7.0% at baseline and 3.4% one year after RYGB (statistical significance not reported).  All 
patients received the same commercial MVI and mineral supplement; however, data on 
compliance were not reported. 
2.3.2.3 Iron deficiency only 
Ikramuddin et al.92 studied a number of outcomes, including prevalence of iron deficiency, in a 
group of 60 subjects (38 women, 22 men, mean age 49 years) one and two years following 
RYGB.  Based on serum ferritin level (criteria to define deficiency not provided), the prevalence 
of iron deficiency was 2.0% prior to surgery, 14.0% at one year after RYGB, and 20.0% two 
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years after RYGB (statistical significance not reported).  Actual mean serum levels were not 
reported.  Ikramuddin et al.92 reported that iron deficiency was more common in women after 
RYGB, but specific data were not provided.  Per the authors, all subjects who underwent RYGB 
were prescribed a MVI and other supplements, including iron.  However, monitoring actual 
usage of prescribed supplements was not a part of the study protocol.   
Bavaresco et al.87 reported the prevalence of iron deficiency, based on serum iron <40 
µg/dl, was 12.2% prior to surgery and 14.6% one year after RYBG (statistical significance was 
not reported) in a study of 48 patients (41 women, 7 men, mean age 41.9 years). The patients 
were instructed to take vitamin and mineral supplements during the postoperative period and 
compliance was monitored at follow-up visits but data on compliance were not reported. 
2.3.3 Folate or iron deficiency following laparoscopic adjustable gastric banding, sleeve 
gastrectomy, and Roux-en-Y gastric bypass – studies with multiple surgery groups 
Toh et al.93 conducted a study to determine the prevalence of a number of micronutrient 
deficiencies, including folate and iron, in a group of 232 subjects (149 women, 83 men, mean 
age 46 years) prior to and one year after LSG, RYGB, and LAGB.  All subjects, regardless of 
type of surgery, were instructed to take a liquid MVI and mineral supplement daily after surgery.  
In addition, RYGB patients were instructed to take a calcium supplement, vitamin B12 
injections, and iron supplements, if they were determined to be deficient based on serum testing.   
Results were available for 149 patients (103 RYGB, 46 LSG) one year after surgery.  
Due to a lack of postoperative biochemistry results for the subjects who underwent LAGB, 
results were only reported for the RYGB and LSG subjects.  For subjects in the RYGB group, 
the prevalence of folate deficiency, defined as RBC folate <776 nmol/L, increased significantly 
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from the preoperative period to one year after RYGB with levels of 1.0% vs. 12.0%, respectively 
(p<.01).   Mean RBC folate level decreased from 1616 nmol/L prior to surgery to 1217 nmol/L 
one-year postoperative (p<.01).  The prevalence of iron deficiency, defined as serum ferritin <15 
µg/L (equivalent to <15 ng/mL), also increased significantly from 2.0% prior to surgery to 
15.0% at one year after surgery (p<.01), and the mean serum ferritin level decreased from 170 
µg/L at baseline to 117 µg/L one year following surgery (p<.01).   In the LSG group, 7.0% of the 
subjects were folate deficient preoperatively, but no subjects were deficient one year following 
surgery.  Mean RBC folate levels were 1582 nmol/L and 1504 nmol/L at baseline and one-year 
after LSG, respectively.  The difference in prevalence of folate deficiency and change in mean 
RBC folate levels were not statistically significant.  None of the subjects were iron deficient 
prior to surgery or one year following LSG.  However, serum ferritin levels did decrease from 
152 µg/L at baseline to 143 µg/L one year after surgery (p<.05).    
Coupaye et al.94 studied the prevalence of micronutrient deficiencies one year after 
LAGB and RYGB.  Of the 70 subjects, 21 had undergone LAGB (18 women, 3 men, mean age 
35 years) and 49 had undergone RYGB (45 women, 4 men, mean age 43 years).  All patients 
who underwent RYGB were prescribed a MVI supplement, which also contained calcium and 
iron, as well as intramuscular vitamin B12 supplementation.   
For the LAGB group, the prevalence of folate deficiency, defined as serum folate <3 
µg/L (equivalent to <3 ng/mL), was 5.0% prior to surgery and 10.0% one year after surgery; 
however, this change was not statistically different.  The mean serum folate levels in the LAGB 
group were 7.1 µg/L at baseline and 5.7 µg/L one year after surgery.  This decrease was not 
statistically significant.  In contrast, mean serum folate levels increased significantly (p<.001) 
from 6.1 µg/L prior to surgery to 17.6 µg/L one year after RYGB.  The difference in the 
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prevalence of folate deficiency, 4.0% prior to surgery and 0% one year after RYGB, was not 
significant.  The prevalence of iron deficiency, based on serum ferritin <3 µg/L (equivalent to <3 
ng/mL), was 15.0% before surgery and 5.0% after LAGB.  This change in prevalence was not 
significant.  Mean serum ferritin levels in the LABG group were similar at both time points (86.3 
µg/L prior to surgery vs. 86.8 µg/L one year after surgery).  In the RYGB group, the prevalence 
of iron deficiency was similar at both time points with 2.0% of subjects deficient in iron prior to 
surgery and 4.0% after RYGB.  The mean serum ferritin levels were 96.4 µg/L at baseline and 
69.8 µg/L one year after surgery; however, this change was not significant.  
In a smaller study of 86 subjects, Coupaye et al.95 compared the prevalence of folate and 
iron deficiency one year after LSG and RYGB.  The subjects were matched for age, gender, and 
weight six months after surgery.  There were 43 subjects in the LSG group (31 women, 12 men, 
mean age 45 years) and 43 subjects in the RYGB group (31 women, 12 men, mean age 44 
years).  Multivitamin supplements, also containing the minerals iron and calcium, were provided 
to patients with deficiencies identified prior to surgery.  After surgery, this MVI and mineral 
supplement was prescribed for all patients.  In the LSG group, the prevalence of folate 
deficiency, defined as serum folate <3 µg/L, remained constant with 7.0% of subjects deficient 
prior to surgery and one year following surgery.  Serum folate levels increased significantly from 
6.6 µg/L at baseline to 11.0 µg/L one year after LSG (p<.001).  For the RYGB group, the 
prevalence of folate deficiency was 7.0% at baseline and 3.0% one year after surgery; however, 
this change in prevalence was not significant.  Similar to the LSG group, serum mean serum 
folate levels increased from 6.2 µg/L at baseline to 14.0 µg/L one-year after RYGB (p<.001).  
Coupaye et al.95 obtained both serum ferritin and transferrin saturation levels, but used 
transferrin saturation of <20% to determine the prevalence of iron deficiency.  The prevalence of 
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iron deficiency in the LSG group decreased significantly from 53.0% of subjects prior to surgery 
to 30.0% one year after LSG (p<.05).   Mean transferrin saturation increased from 19.3% to 
24.8% (p<.01).  The change in mean serum ferritin from 168.7 µg/L at baseline to 184.4 µg/L 
one year after LSG was not statistically significant.   Prevalence of iron deficiency also 
decreased in the RYGB group with 49.0% of subjects deficient at baseline compared to 20.0% of 
subjects one year after surgery (p<.01).  In the RYGB group, mean transferrin saturation 
increased from 19.8% at baseline to 25.1% one-year following surgery (p<.01).  The mean serum 
ferritin levels, 134.8 µg/L prior to surgery and 97.3 µg/L after surgery, were not significantly 
different. 
2.3.4 Summary of findings 
2.3.4.1 Folate deficiency after bariatric surgery 
The prevalence of folate deficiency one year after RYGB ranged from 0% - 12.0% in six 
studies.89-91,93-95  Of these studies, only Toh et al.93 reported a significant increase in the 
prevalence of folate deficiency from baseline to one year following RYGB.  Three studies89-91 
did not report statistical significance of difference in prevalence.  For the three LSG 
studies88,93,95, the prevalence of folate deficiency one year after surgery ranged from 0% - 8.0% 
and none reported a statistically significant difference in the prevalence of folate from baseline to 
one year following surgery.  For LAGB, Coupaye et al.94 reported that the prevalence of 
deficiency one year after surgery was not significantly different from baseline.       
30 
2.3.4.2 Iron deficiency after bariatric surgery 
Seven studies87,89,90,92-95 compared the preoperative and one-year postoperative prevalence of 
iron deficiency after RYGB.  The prevalence of iron deficiency one year following RYGB in 
these studies ranged from 4.0% - 20.0%.  Of these studies, only Toh et al.93 reported a significant 
increase in the prevalence of iron deficiency from baseline to one year following RYGB.  In 
contrast, Coupaye et al.95 reported that the prevalence of iron deficiency decreased significantly 
from baseline to one year after RYGB.   The other three studies87,90,92 did not report statistical 
significance of differences.  Three studies88,93,95 compared baseline to one-year postoperative 
prevalence of iron deficiency after LSG.  Vage et al.88 reported a significant increase in the 
prevalence of iron deficiency one year after LSG; while Coupaye et al.95 reported a significant 
decrease.  Toh et al.93 found no significant difference in the prevalence of iron deficiency at the 
two time points.  Only one study94 investigated the prevalence of iron deficiency prior to and one 
year after LAGB, and the difference in prevalence of deficiency was not statistically significant.   
2.3.4.3 Study characteristics 
The number of subjects ranged from 48 – 170, with a median of 74 subjects.  All of the studies 
had a larger percentage of women compared to men; however, none of the studies stratified the 
results for folate or iron deficiency by sex.  The mean age of the subjects ranged from 35 – 49 
years.  Researchers measured serum folate levels to diagnose folate deficiency, except for Toh et 
al.93 who used RBC folate levels.  The serum biomarker used to identify iron deficiency varied 
between studies.  Six studies88-90,92-94 used serum ferritin, one study 87 used serum iron, and one 
study95 used transferrin saturation.  As presented previously in Table 4, these biomarkers vary in 
what is measured, the phase of iron deficiency detected, and other factors that can cause a 
decreased serum value.  Another factor that varied between studies was the laboratory cutoffs 
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used to define folate and ferritin deficiency.  The definition of folate deficiency based on serum 
folate ranged from 2.21 – 3.97 ng/mL.  For studies that used serum ferritin to identify iron 
deficiency, the criteria ranged from 3 – 25 ng/mL.  Studies that used a serum level on the low 
end of the range (e.g. Coupaye et al.94) would classify less individuals as deficient based on the 
stricter criteria compared to a study that used a higher serum ferritin level (e.g. Vage et al.88).  
This could explain some of the difference in the prevalence of deficiency.    
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Table 5:  Summary of studies comparing preoperative and postoperative prevalence of folate or iron deficiency  
Author, year 
(Location) 
Surgery Baseline sample size, 
gender, mean age (y) 
Indicator of deficiency 
(criteria for defining 
deficiency)  
Recommended 
supplementation 
post-op 
Prevalence of 
folate 
deficiency: 
baseline vs. 1-
year post-op 
(p-value)  
Prevalence of 
iron 
deficiency: 
baseline vs. 1-
year post-op 
(p-value) 
Vage, 201488 
(Norway) 
LSG 117 subjects (87 women, 
30 men, 40.3 y) 
Serum folate (<5 nmol/L 
equivalent to <2.21 
ng/mL) 
Serum ferritin (<25 µg/L 
equivalent to <25 ng/mL) 
MVI daily; 
74% of subjects reported 
taking MVI daily at 12-
month follow-up  
7.5% vs. 8.0% 
(p=1.0, NS) 
↑ 11.2% vs. 
19.8% (p=.02) 
Bavaresco, 
201087 (Brazil) 
RYGB 48 subjects (41 women, 
7 men, 41.9 y) 
Serum iron (<40 µg/dL) Vitamin and mineral 
supplementation daily  
(specific information 
NR) 
N/A 12.2% vs.  
14.6 % (NR) 
Blume, 201289 
(Brazil) 
RYGB 170 subjects (136 
women, 34 men 39.5 y) 
Serum folate (<2.8 ng/mL) 
Serum ferritin (<10 
ng/mL) 
72% of subjects reported 
taking a combination of 
individual vitamin or 
mineral supplements 
(MVI, iron, folic acid, or 
vitamin B12) 
6.5% vs. 1.2% 
(NR) 
5.3% vs. 4.1% 
(NR) 
Donadelli, 
201291 (Brazil) 
RYGB 58 subjects (46 women, 
12 men, 42 y) 
Serum folate (<3 ng/mL) MVI with minerals daily 7.0% vs. 3.4% 
(NR) 
N/A 
Dogan, 201490 
(The 
Netherlands) 
RYGB 74 subjectsa (51 women, 
23 men, 43.4 y) 
Serum folate (<9 nmol/L 
equivalent to 3.97 ng/mL) 
Serum ferritin (<20 µg/L 
equivalent to <20 ng/mL) 
MVI with minerals 
including iron daily 
1.4% vs. 6.8% 
(NR) 
6.7% vs. 
10.7% (NR) 
Ikramuddin, 
201592 (U.S. 
and Taiwan) 
RYGB 60 subjects (38 women, 
22 men, 49 y) 
Serum ferritin (NR) MVI and iron 
supplement daily 
N/A 2.0% vs. 
14.0% (NR) 
Abbreviations: y: years; post-op: post-operative; LSG: laparoscopic sleeve gastrectomy; RYGB: Roux-en-Y gastric bypass; LAGB: laparoscopic 
adjustable gastric banding; MVI: multivitamin; NR: not reported; NS: not statistically significant; N/A: not applicable for the individual study 
Symbols: ↑: prevalence of deficiency increased significantly from baseline to 1-year post-op 
aReporting only data from the standard multivitamin with minerals supplement group. 
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Table 5 (continued):  Summary of studies comparing preoperative and postoperative prevalence of folate or iron deficiency  
Author, year 
(Location) 
Surgery Baseline sample 
size, gender, mean 
age (y) 
Indicator of deficiency 
(criteria for defining 
deficiency) 
Recommended 
supplementation 
post-op 
Prevalence of 
folate 
deficiency: 
baseline vs. 1-
year post-op (p-
value)  
Prevalence of iron 
deficiency: 
baseline vs. 1-year 
post-op (p-value) 
Toh, 200993b 
(Australia) 
 
LSG  
 
46 (NR, NR) 
 
RBC folate (<776 nmol/L) 
Serum ferritin (<15 µg/L 
equivalent to <15 ng/mL) 
MVI with minerals daily 7.0% vs. 0% 
(NS) 
0% vs. 0%  
 
RYGB 103 (NR, NR) MVI with minerals daily ↑ 1.0% vs. 
12.0% (p<.01) 
↑ 2.0% vs. 15.0% 
(p<.01) 
Coupaye, 
200994 
(France) 
 
 
LAGB  21 (18 women, 3 
men, 35 y) 
 
Serum folate (<3 µg/L 
equivalent to <3 ng/mL) 
Serum ferritin (<3 µg/L 
equivalent to <3 ng/mL) 
None 5.0% vs. 10.0% 
(NS) 
 
15.0% vs. 5.0% 
(NS) 
 
RYGB 49 (45 women, 4 
men, 43 y) 
MVI containing iron and  
calcium daily;  
intramuscular vitamin B12  
4.0% vs. 0% 
(NS) 
2.0% vs. 4.0% 
(NS) 
Coupaye, 
201495 
(France) 
 
LSG  43 (31 women, 12 
men, 45 y) 
 
Serum folate (<3 µg/L 
equivalent to <3 ng/mL) 
Transferrin saturation 
(<20%) 
MVI containing iron and  
calcium daily 
7.0% vs. 7.0%  
 
↓ 53.0% vs. 30.0% 
(p<.05) 
 
RYGB 43 (31 women, 12 
men, 44 y) 
MVI containing iron and  
calcium daily   
7.0% vs. 3.0% 
(NS) 
RYGB: ↓ 49.0% 
vs. 20.0% (p<.01) 
Abbreviations: y: years; post-op: post-operative; LSG: laparoscopic sleeve gastrectomy; RYGB: Roux-en-Y gastric bypass; LAGB: laparoscopic 
adjustable gastric banding; RBC: red blood cell; NR: not reported; NS: not statistically significant; N/A: not applicable for the individual study 
Symbols: ↑: prevalence of deficiency increased significantly from baseline to 1-year post-op; ↓: prevalence of deficiency decreased significantly 
from baseline to 1-year post-op  
b232 subjects (149 women, 83 men, 46 y) at baseline. Results available for 149 subjects (sex and mean age NR). 
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2.4 FOLATE AND IRON DEFICIENCY - COMPARISON BETWEEN BARIATRIC 
SURGERIES 
Three studies compared the prevalence of micronutrient deficiencies, including folate and iron, 
between different types of bariatric surgeries met the inclusion/exclusion criteria for this review.  
Two of the studies, Coupaye et al.94 and Coupaye et al.95, also compared preoperative and 
postoperative prevalence of deficiency and are included in both the prior section and this section 
for discussion.  Table 6 provides a summary of the main characteristics and results of these 
studies. 
2.4.1 Laparoscopic adjustable gastric banding versus Roux-en-Y gastric bypass 
Coupaye et al.94 compared the prevalence of folate and iron deficiency one year after LAGB and 
RYGB (the details of the study were described previously in section 2.3.3).  Mean serum folate 
level was significantly lower following LAGB (5.7 µg/L) than RYGB (17.6 µg/L) (p<.001), and 
there was a significantly higher prevalence of folate deficiency at one year after LABG (10.0%) 
when compared to RYGB (0%) (p<.05).  Mean serum ferritin level one year after RYGB was 
69.8 µg/L compared to 86.8 µg/L after LAGB; however, this difference was not significant.  The 
prevalence of iron deficiency one year after LAGB was 5.0% compared to 4.0% after RYGB, 
which was not statistically different.  
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2.4.2 Sleeve gastrectomy versus Roux-en-Y gastric bypass 
In another study, Coupaye et al.95 compared the prevalence of folate and iron deficiency one year 
after LSG and RYGB (the details of the study were described in section 2.3.3).  Mean serum 
folate levels were not statistically different one year after LSG and RYGB, with values of 11.0 
µg/L vs. 14.0 µg/L, respectively.  The researchers reported the prevalence of folate deficiency 
one year following surgery, 7.0% for LSG vs. 3.0% for RYGB, was not statistically different.  
The prevalence of iron deficiency, based on transferrin saturation, was 30.0% one year after LSG 
and 20.0% after RYGB; however, the difference was not statistically significant.  Similarly, 
mean transferrin saturation was not statistically different between the two surgeries one year 
after surgery, with values of 24.8% for the LSG group and 25.1% for the RYGB group.  
However, mean serum ferritin level was significantly lower (p<.05) at one year following RYGB 
when compared to one year after LSG (97.3 µg/L vs. 184.4 µg/L, respectively).  The researchers 
noted one year following surgery, 93% of patients in the RYGB group were taking the 
recommended MVI supplement compared to 53% of LSG patients (p<.01).  
Gehrer et al.63 compared the rates of micronutrient deficiencies over a 36-month time 
period following bariatric surgery for subjects who had a LSG or a laparoscopic RYGB.  The 
study had 136 subjects, with 50 subjects (37 women, 13 men, mean age 41.9 years) in the LSG 
group and 86 subjects (61 women, 25 men, mean age 43.5 years) in the RYGB group.  All 
subjects were prescribed a daily MVI supplement, which also included calcium, magnesium, and 
zinc, to be taken postoperatively.  Folate deficiency was defined by serum folate < 6 nmol/L 
(equivalent to <2.65 ng/mL), and serum ferritin < 30 ng/mL indicated iron deficiency.  Mean 
serum levels were not reported.  One year after surgery, the prevalence of folate deficiency in the 
LSG group was 16.0% compared to 9.0% in the RYGB group.  The prevalence of iron 
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deficiency was 16.0% one year after LSG and 24.0% after RYGB.  Statistical testing for 
significance of between-group differences was not reported at one year.   
2.4.3 Summary of findings between surgeries 
Only three studies were identified that compared the prevalence of folate or iron deficiency 
between the bariatric surgeries of interest one year after surgery and met the inclusion/exclusion 
criteria for this review.  One study94 compared results for LAGB and RYGB.  The prevalence of 
folate deficiency was significantly greater after LAGB when compared to RYGB.  The 
prevalence of iron deficiency was similar for both surgery groups.  Coupaye et al.94 did not 
control or adjust for potential confounding.  The authors did not report sample size calculations 
or power level; however, based on the small sample size the study may have been underpowered. 
Two studies63,95 compared the prevalence of folate and iron deficiencies one year after 
surgery for subjects who underwent LSG and RYGB.  Coupaye et al.95 did not find a statistically 
significant difference in the prevalence of folate deficiency or iron deficiency between surgeries 
at one year after surgery.   The subjects were matched for age, gender, and weight six months 
after surgery to control for potential confounding.  Coupaye et al.94 noted their study lacked 
power for statistical comparisons; however, the power level for the study was not reported. 
Gehrer et al.63 did not report statistical testing at the one-year time point after surgery for either 
nutrient deficiency.   Gehrer et al.63 did not control or adjust for potential confounding.  The 
authors did state the LSG and RYGB groups were similar in age, preoperative BMI, and gender. 
The number of subjects ranged from 70 - 136.  The mean age of the subjects ranged from 
35 – 45 years.  All three studies63,94,95 used serum folate levels to diagnose folate deficiency and 
similar criteria to define deficiency.  For identification of iron deficiency, one study95 used 
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transferrin saturation and two studies63,94 used serum ferritin.  Coupaye et al.94 defined deficiency 
as serum ferritin <3 ng/mL while Gehrer et al.63 defined deficiency as <30 ng/mL.  This 
difference in criteria used could explain, in part, the lower prevalence of iron deficiency 
identified one year after surgery by Coupaye et al.94 (5.0% after LAGB and 4.0% after RYGB) 
compared to Gehrer et al.63 (16.0% after LSG and 24.0% after RYGB).  
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Table 6: Summary of studies comparing the prevalence of folate and iron deficiency one year post-surgery between bariatric 
surgeries 
Abbreviations: y: years; post-op: post-operative; LAGB: laparoscopic adjustable gastric banding; LSG: laparoscopic sleeve gastrectomy; RYGB: 
Roux-en-Y gastric bypass; MVI: multivitamin; NR: not reported; NS: not statistically significant 
Author, year 
(Location) 
Surgery Baseline total and 
group sample sizes, 
women vs. men, mean 
age (y) 
Indicator of 
deficiency (criteria 
for defining 
deficiency) 
Recommended 
supplementation 
post-op 
Prevalence of folate 
deficiency at 1-year 
post-op (p-value for 
between surgery 
comparisons)   
Prevalence of iron 
deficiency at 1-year 
post-op 
(p-value for between 
surgery comparisons)    
Coupaye, 
200994 
(France) 
 
 
LAGB 
vs. 
RYGB 
70 subjects: 
21 LAGB (18 women, 
3 men, 35 y) 
49 RYGB (45 women, 
4 men, 43 y) 
Serum folate (<3 
µg/L equivalent to 
<3 ng/mL)  
Serum ferritin (<3 
µg/L equivalent to 
<3 ng/mL) 
LAGB: none 
RYGB: MVI 
containing iron and  
calcium daily; 
intramuscular vitamin 
B12 
LAGB: 10.0%  
RYGB: 0% 
LAGB > RYGB 
(p<.05) 
   
LAGB: 5.0%  
RYGB: 4.0% 
(NS) 
Coupaye, 
201495 
(France) 
 
 
LSG  
vs. 
RYGB 
86 subjects: 
43 LSG (31 women, 
12 men, 45 y) 
43 RYGB (31 women, 
12 men, 44 y) 
Serum folate (<3 
µg/L equivalent to 
<3 ng/mL) 
Transferrin 
saturation (<20%) 
MVI containing iron 
and calcium daily 
LSG: 7.0%  
RYGB: 3.0% 
(NS) 
LSG: 30.0%  
RYGB: 20.0%  
(NS) 
Gehrer, 
201063 
(Switzerland) 
 
 
LSG  
vs. 
RYGB 
136 subjects: 
50 LSG (37 women, 
13 men, 41.9 y) 
86 RYGB (61 women, 
25 men, 43.5 y) 
Serum folate (< 6 
nmol/L equivalent 
to <2.65 ng/mL) 
Serum ferritin  
(< 30 ng/mL) 
MVI containing 
calcium, magnesium, 
and zinc daily 
LSG: 16.0%  
RYGB: 9.0%  
(NR) 
LSG: 16.0%  
RYGB: 24.0%  
(NR) 
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2.5 SUMMARY 
2.5.1 Study quality and limitations 
2.5.1.1 Sample size and power 
A significant limitation to the majority of the studies was sample size.  The number of subjects in 
the studies reported ranged from 48 – 170, with a median of 80 subjects.   Studies with small 
sample sizes may not have had adequate power to detect meaningful differences in results as 
statistically significant.  For example, the study by Coupaye et al.94, which only had 70 subjects 
(21 in the LAGB group and 49 in the RYGB group), did find significant differences in the 
prevalence of folate or iron deficiency between baseline to one year after surgery for either group 
or for the prevalence of iron deficiency between the two surgery groups. 
Only two studies included sample size calculations and estimated power.  Dogan et al.90 
conducted sample size calculations to detect a 25% reduction in iron deficiency between study 
groups (standard MVI with minerals vs. specialized supplement) one year after surgery.  The 
researchers determined 75 subjects were needed per group, for a total of 150 subjects, to provide 
90% power.  Two subjects were excluded after randomization.  Included in the analyses were 
148 subjects with 74 per group.  Ikramuddin et al.92 reported 90% power for their study of 120 
subjects (60 per group).  However, the sample size calculation was based on percent success in 
reduction of glycated hemoglobin, an indicator of glycemic control, between study groups 
(RYGB vs. lifestyle and medical management for obesity) which is not a variable relevant to this 
review.   
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2.5.1.2 Statistical testing  
A common factor among the majority of the studies reviewed was a lack of testing for statistical 
significance between preoperative and postoperative prevalence of folate and iron deficiency or 
differences between surgery groups.  Of the studies that met the inclusion/exclusion for this 
review, only four88,93-95 out of ten reported statistical testing of differences in prevalence one year 
postoperatively.  Inadequate statistical power may have been the rationale for the lack of 
statistical tests reported in some studies. 
2.5.1.3  Definition of deficiencies 
Researchers used different serum biomarkers to identify deficiencies.  For folate deficiency, 
serum folate was used in all studies, except for Toh et al.93 who used RBC folate levels.  For 
identification of iron deficiency, seven studies63,88-90,92-94 used serum ferritin, one study 87 used 
serum iron, and one study95 used transferrin saturation.  As presented previously in Table 3 and 
Table 4, these biomarkers vary in what is measured, the time period of deficiency identified, and 
other factors besides nutrient deficiency that can affect serum level.   
In addition, there was variation in the laboratory cutoffs used to define folate and ferritin 
deficiency.  The definition of folate deficiency using serum folate ranged from 2.21 – 3.97 
ng/mL.  For studies that used serum ferritin to identify iron deficiency, the criteria ranged from 3 
– 30 ng/mL.  The use of different serum levels to diagnose deficiency could account for some of 
the differences in prevalence of deficiency with studies using stricter criteria classifying less 
individuals as deficient compared to studies that used a higher serum level.  
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2.5.1.4 Vitamin and mineral supplement usage 
Another major limitation was a lack of consistent data obtained on vitamin and mineral 
supplement usage after surgery.  Recommendations for micronutrient supplementation varied 
between studies, particularly with respect to minerals.  Only a few studies88,89,95 reported data on 
the subjects’ intake of vitamin and mineral supplements. 
2.5.1.5 Stratification of results by sex 
Another limitation of the reviewed studies is none of the studies stratified the results by sex.  
This is relevant to the proposed research because the population of interest is women of child-
bearing age.   
2.5.2 Need for additional research 
While studies have been conducted to determine the prevalence of folate and iron deficiency 
after bariatric surgery, the results are conflicting and study quality has been an issue.  Examining 
the results by procedure, there was no significant difference in the prevalence of folate or iron 
deficiency from baseline to one year after surgery for the one study94 that looked at LAGB.  
None of the LSG studies88,93,95 reported significant differences in preoperative vs. one-year 
postoperative prevalence of folate deficiency.  For iron deficiency following LSG, one study88 
reported a significant increase in prevalence, one study95 reported a significant decrease in 
prevalence, and one study93 reported no significant difference in the prevalence of iron 
deficiency from baseline to one-year following surgery.  One study93 reported a significant 
increase in the prevalence of folate deficiency from baseline to one year after RYGB; while, two 
studies94,95 reported no significant differences.  The prevalence of iron deficiency after RYGB 
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increased significantly in one study93, decreased significantly in another study95, and did change 
significantly from baseline to one-year following surgery in one study94.   For between surgery 
comparisons, the prevalence of folate deficiency was significantly higher one year following 
LAGB compared to RYGB in one study94.   There was no significant difference in the 
prevalence of folate deficiency one year after surgery in a study95 that compared LSG to RYGB.  
No significant differences were reported for the prevalence of iron deficiency one year after 
surgery in a study94 comparing LAGB to RYGB or a study95 comparing LSG to RYGB. 
The proposed study will add to the existing research by addressing the limitations 
previously discussed.  This study will have a larger sample size of 427 subjects, based on sample 
and effect size calculations.  The prevalence of folate and iron deficiencies will be determined as 
well as the change in serum folate and ferritin levels from baseline to one-year after surgery.  
Also, between group comparisons by surgery type will be evaluated.  Differences will be tested 
for statistical significance.  Data on supplement intake will be included in the analysis.  Finally, 
to address the aims of the study, the subjects will be limited to adult females of childbearing age 
only.   
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3.0  METHODOLOGY 
3.1 EXPERIMENTAL DESIGN 
This study involved analyzing stored serum samples from a cohort of childbearing-age women 
before and after having undergone bariatric surgery to determine the change in serum folate and 
serum ferritin levels.  The serum samples were from adult females who participated in the 
Longitudinal Assessment of Bariatric Surgery (LABS) study.  The proposed research was 
approved to be conducted as an ancillary study to the LABS study.  The study was granted 
“exempt” status by the University of Pittsburgh Institutional Review Board on February 19, 
2016. 
  LABS was a multicenter, observational study that collected data on candidates for bariatric 
surgery prior to and following surgery at ten clinical centers throughout the U.S.4,96   LABS had 
three phases.96  The goal of LABS-1 was to evaluate the short-term safety of bariatric surgery.96  
The LABS-1 cohort included 4776 participants with limited clinical data to assess adverse 
outcomes within 30 days after surgery.97  LABS-2 focused on the longer-term safety and efficacy 
of bariatric surgery and collected substantial data on clinical and psychiatric/psychological factors 
including weight, comorbid conditions, and functional impairment.4,96  LABS-3 comprised two 
“mechanistic” studies: a diabetes study and a psychosocial study.98  The diabetes study 
investigated the physiological mechanisms involved in improved glycemic control after RYGB for 
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subjects with type 2 diabetes mellitus.98  The psychosocial study involved subsets of participants 
from LABS-2 and focused on psychosocial and behavioral aspects of obesity.96,99   
3.2 SUBJECTS 
The serum samples analyzed for this ancillary study were from a subset of 426 participants from 
LABS-2 who met all of the inclusion criteria and none of the exclusion criteria specified in 
section 3.2.2.   
3.2.1 Description of the LABS-2 participants 
LABS-2 involved 2458 participants who underwent bariatric surgery between February 2006 and 
April 2009.100  Each participant underwent a first-time bariatric surgery performed by a LABS-
certified surgeon at one of the following centers: University of Pittsburgh Medical Center 
(Pennsylvania),  Columbia University Medical Center and Weill-Cornell University Medical 
Center (New York), University Health Systems of Eastern North Carolina and East Carolina 
University (North Carolina), Neuropsychiatric Research Institute (North Dakota), Oregon Health 
and Science University and Legacy Good Samaritan Hospital (Oregon), and Virginia Mason 
Medical Center and University of Washington (Washington).96,100  Over two-thirds (70.7%) of 
participants underwent a RYGB.  For the participants who underwent a RYGB, the surgery was 
performed laparoscopically in 88.6% of participants and performed as an open procedure in 
11.4% of participants.100  In addition, 24.8% of participants underwent LAGB, and 4.5% had 
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another type of surgery such as SG or BPD with duodenal switch.100  All participants were at 
least 18 years old.96  The median age was 46 years with a range of 18 - 78 years.100    
The LABS-2 cohort included 1931 female participants.4  A summary of selected baseline 
characteristics for the female LABS-2 participants is presented in Table 7.  Of these women, 
50.9% were between the ages of 18-45 years at surgery.4,5  Specifically for these women of 
childbearing age, 74.1% underwent a RYGB, 22.2% LAGB, and 1.9% SG.4,5  While the most 
common bariatric surgical procedure currently performed in the U.S. is the SG1, this was not the 
case in LABS which ended enrollment in 2009.  Thus, due to the low number of LABS-2 
participants who underwent this procedure, only RYGB and LAGB participants were included. 
 
Table 7:  Summary of selected baseline characteristics for all LABS-2 female participants 
(n = 1931) 
 
Baseline Characteristic Results 
Age in years - median (quartiles) 45 (36, 54) 
Childbearing age range of 18-45 years at surgery – n (%) 984 (50.9%) 
Race – n (%): 
     White 
     Black 
     Multiple races 
     Other 
 
1623 (84.6%) 
224 (11.7%) 
43 (2.2%) 
28 (1.5%) 
Ethnicity – n (%): 
     Hispanic  
     Non-Hispanic 
 
101 (5.2%) 
1829 (94.8%) 
BMI in kg/m2 – median (quartiles) 45.7 (41.6, 51.0) 
Source: Adapted from Tables 1 and 2 of: Belle SH, Berk PD, Chapman WH, et al. Baseline 
characteristics of participants in the Longitudinal Assessment of Bariatric Surgery-2 (LABS-2) study. 
Surg Obes Relat Dis. 2013;9(6):926-935.100 
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3.2.2 Inclusion criteria 
The subjects for this ancillary study were randomly selected by LABS DCC staff from the group 
of LABS-2 participants who met the following inclusion criteria: 
• female participants of the LABS-2 study 
• in the childbearing age range of 18-45 years at surgery 
• had both preoperative and one-year postoperative serum samples stored at the National 
    Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Biospecimen Repository  
• underwent either a RYGB (laparoscopic or open procedure) or a LAGB.    
3.2.3 Exclusion criteria 
Subjects were excluded from the study if: 
• either the preoperative or one-year postoperative serum sample was hemolyzed.  
 
For generalizability, the subjects were of varying races and ethnicities and from different 
LABS clinical centers.  A visual representation of recruitment of participants for LABS-2 and 
flow to the current study is shown in Figure 6. 
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Figure 6:  Flowchart of recruitment for LABS-2 and the current study. 
Adapted from Figure 1 of Belle SH, Berk PD, Chapman WH, et al. Baseline characteristics of participants in the 
Longitudinal Assessment of Bariatric Surgery-2 (LABS-2) study. Surg Obes Relat Dis. 2013;9(6):926-935100 and 
Figure of King WC, Chen J, Mitchell JE, et al. Prevalence of alcohol use disorders before and after bariatric surgery. 
JAMA. 2012;307(23):2516-2525101. 
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3.3 SAMPLE SIZE AND POWER ANALYSIS 
Sample size calculations were conducted to determine the number required to obtain estimates 
within 5% of the true prevalence of deficiency of folate and iron, individually, with a confidence 
level of 95%.  Sample sizes were calculated using the formula by Daniel102 and prevalence data 
from the study by Gehrer et al.63 to estimate the true prevalence of folate and iron deficiency 
after LSG and RYGB.  Due to a lack of available data on prevalence of folate and iron 
deficiency after LAGB, LSG data from the Gehrer et al.63 study were used.  Gehrer et al.63 
reported prevalence of 16% for folate deficiency and 16% for iron deficiency one year after LSG 
and 9% for folate deficiency and 24% for iron deficiency one year after RYGB.  Based on these 
data, a sample size of 206 LAGB subjects was needed to obtain an estimate of the prevalence of 
folate deficiency and 206 subjects to obtain an estimate of the prevalence of iron deficiency one 
year after surgery with the precision noted above.  For RYGB, 126 subjects were needed for the 
prevalence of folate deficiency and 280 subjects for the prevalence of iron deficiency one year 
after surgery with the precision noted above.   
The largest sample size required for estimating prevalence was selected resulting in a 
target sample size of 280 RYGB and 280 LAGB subjects.  The 280 RYGB subjects were a 
random sample of the 729 LABS-2 female participants who underwent RYGB and met the 
inclusion criteria for the study.   However, there were only 218 LABS-2 female participants who 
underwent LAGB and of these participants only 147 met the inclusion criteria for the study with 
the age criteria being the limiting factor.   
Since data collection for LABS-2 is complete, the sample size is fixed and funding for 
this ancillary study was limited, so, using the sample sizes derived above, effect size calculations 
were conducted to address the second aim of the study, which was to determine if the change in 
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serum folate level and serum ferritin level from baseline to one-year following bariatric surgery 
for women of childbearing age differed by type of bariatric surgery - RYGB vs. LAGB.  PASS 
version 14 (NCSS Statistical Software) was used to conduct the effect size calculations.  With 
sample sizes of 280 RYGB subjects and 147 LAGB subjects, there was 80% power to reject the 
null hypothesis of equal means of folate or ferritin levels between subjects in each surgery group 
when the effect size is 0.3, with α <.05, using a two-sided two-sample equal-variance t-test.  An 
effect size of 0.3 based on Cohen’s d is considered “small” to “medium”.103   
For the third aim of the study, which was to identify factors associated with change in 
serum folate and serum ferritin levels from baseline to one year after RYGB among women of 
childbearing age, PASS version 14 (NCSS Statistical Software) was used to calculate the 
minimum R-squared of independent variables in a linear regression model that can be detected 
based on the sample size.  With a sample size of 280 subjects, there was 80% power to detect an 
R-squared of 0.07 attributed to 20 independent variables using an F-Test with α <.05. 
3.4 OUTCOME MEASURES AND ASSESSMENT 
The primary outcome measures for the study were the change in serum folate and serum ferritin 
levels from baseline (preoperative) to one year after RYGB or LAGB.  The secondary outcomes 
were the prevalence of folate and iron deficiencies one year after RYGB or LABG.  Serum levels 
of both micronutrients were determined from each participant’s serum sample following the 
methods described below.  Both preoperative and one-year postoperative serum levels were 
determined for each subject.  The serum analyses were conducted by staff at the Heinz Nutrition 
Laboratory at the University of Pittsburgh’s Graduate School of Public Health under the 
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guidance of the Lab Director, Joseph M. Zmuda, PhD, Associate Professor of Epidemiology and 
Beth Ann Hauth, Lab Manager.  Per the request of the Lab Manager, both the preoperative and 
one-year postoperative serum sample for each subject were analyzed in the same batch of 30 
samples.  However, the serial identification numbers were masked so the lab technicians did not 
know which samples came from the same subject.  
3.4.1 Determining folate status 
Folate status was determined by the serum folate level measured using a microbiological assay 
provided by ALPCO (Salem, NH).  For the folate analysis, 300 µL of serum was required.  
Diluted samples were added to microtiter plate wells coated with Lactobacillus rhamnosus.  
During incubation at 37°C for 48 hours, the growth of the bacteria is directly related to the 
concentration of folate.  Growth was measured by spectrophotometry at 610-630 nm.  Standards, 
blanks, and control pools were run with each set of samples.  The inter- and intra-assay 
coefficients of variation for the controls were 10.2% and 7.1%, respectively.  The intra-assay 
coefficient of variation for the subjects’ samples was 3.7%.  The folate assay was repeated if the 
optical density of the sample reached or exceeded the highest standard’s optical density of 
approximately 0.95 units with the diluted value from the repeated assay used as the final result.   
The normal range of serum folate for adult females is 5-25 ng/mL.55  Deficiency has been 
defined as serum folate <3 ng/mL for adult females.56,57    The normal range for serum folate in 
the first trimester of pregnancy has been reported to be 2.6-15.0 ng/mL.104  However, deficiency 
criteria for pregnancy are uncertain.58  Folate deficiency was defined as serum folate <3 ng/mL.  
51 
3.4.2 Determining iron status 
Iron status was determined by serum ferritin level analyzed using an immuno-spectrophotometric 
method with reagents obtained from Beckman-Coulter (Brea, CA).  The volume of serum needed 
for the analysis from each sample was 100 µL.  The serum was incubated with a suspension of 
latex beads coated with a polyclonal rabbit anti-ferritin antibody.  After agglutination occurred, 
the absorbance was measured at 660 nm.  Blanks, calibrators, and control pools were run with 
each set of samples.  The inter- and intra-assay coefficients of variation for the controls were 
5.0% and 2.7%, respectively.  The intra-assay coefficient of variation for the subjects’ samples 
was 3.7%.  The assay was repeated for serum ferritin levels of less than 8 ng/mL and for values 
higher than 300 ng/mL with the initial values used as the final result.  The normal range for 
serum ferritin for adult females is 10-150 ng/mL.55   Iron deficiency has been defined as serum 
ferritin level <15 ng/mL for adult females.79,81  Similarly, for pregnant women, the criteria for 
diagnosing iron deficiency is serum ferritin <10-15 ng/mL.105   Iron deficiency was defined as 
serum ferritin <15 ng/mL.  
3.4.3 Time points for analyzing serum samples 
To address the second aim of the study, the difference between serum folate and serum ferritin 
levels were determined for each subject from their baseline (preoperative) serum samples to their 
one-year postoperative follow-up samples.  Serum folate and serum ferritin levels were also used 
to determine folate and ferritin deficiencies at both time points. The one-year postoperative 
follow-up visit was selected as the beginning of the 12-18 month recommended waiting period 
for women to avoid becoming pregnant following bariatric surgery.11     
52 
3.4.4 Procurement of stored serum samples 
The serum samples obtained from the LABS-2 participants were stored at the NIDDK 
Biospecimen Repository.  After receiving approval from the LABS Steering Committee to 
conduct an ancillary study and use serum samples from participants, a Material Transfer 
Agreement/Sample and Data Use Agreement was completed between the University of Pittsburgh 
and the NIDDK Central Repositories.  The LABS DCC staff developed a list of serum samples 
from the randomly selected subjects to be requested from the NIDDK Central Repositories.  With 
two samples from each of the 427 subjects, a total of 854 serum samples were requested.  The 
analysis required a total of 400 µL of serum per sample (300 µL for the folate analysis and 100 µL 
for the ferritin analysis).   
3.5 ADDITIONAL VARIABLES 
Data on additional variables of interest were provided by LABS DCC staff.  The variables were 
collected by LABS-trained personnel or participant self-report using standardized instruments 
and forms.4,96,100  If data were not reported, they were designated as “missing”. 
Type of bariatric surgery, RYGB or LAGB, and age at surgery were reported.  Baseline 
BMI was calculated as weight in kilograms divided by height in meters squared using weight and 
height obtained at baseline.  Pregnancy status (pregnant, potentially pregnant, or not pregnant) at 
the one-year postoperative visit was self-reported.     
  Percent weight change is the percentage of the individual’s preoperative body weight 
that was lost, or gained, between baseline and the one-year follow-up visit.106  Percent weight 
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change was calculated as weight at baseline minus weight at the one-year postoperative follow-
up visit divided by weight at baseline, and multiplied by 100.  Thus, a positive value indicates 
weight loss and a negative value indicates weight gain.  Weight data were excluded for any 
subjects who were pregnant at the time of the one-year postoperative visit.   
Race and ethnicity were of interest due to the potential association with folate and iron 
deficiency.  Race was self-reported with participants able to select one or more of the following: 
White, Black, Asian, American Indian or Alaska Native, Native Hawaiian or other Pacific 
Islander, or other.  Due to the low number of participants identifying as Asian, American Indian 
or Alaska Native, Native Hawaiian or other Pacific Islander, or of multiple races, these races 
were combined and categorized as “other or of multiple races”.  Ethnicity was self-reported as 
Hispanic or non-Hispanic. 
Data on MVI, MVI with minerals, iron, and folate supplement use were used to 
investigate the hypothesis that micronutrient supplement use is significantly associated with 
change in serum folate and serum ferritin levels.  A MVI is a supplement that contains a 
combination of different water-soluble and fat-soluble vitamins.  MVI use was included as a 
variable for the folate analyses because MVI supplements commonly include folate.  MVI with 
minerals use is relevant to the serum ferritin analyses because these usually, but not always, 
contain iron.  These data were self-reported by participants at baseline and the one-year 
postoperative visit.96  Participants were asked to report if they had taken a MVI or an individual 
vitamin or mineral supplement (including folate or iron) within the past 90 days, and, if so, to 
report frequency of use as daily, weekly, monthly/rarely, or no longer taking.  Participants who 
reported taking a MVI were also asked if the MVI included minerals.  For the folate analyses, all 
participants who reported taking a MVI or MVI with minerals at least weekly were classified as 
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taking a MVI.  For frequency of supplement use, the categories of monthly/rarely and no longer 
taking were combined due to the low level of micronutrients that would be provided with 
infrequent supplement use.  When examining the change in serum folate and ferritin, a multiple 
category variable was created for each type of supplement to compare the use of the supplement 
on a daily/weekly basis at baseline only, follow-up only, both time points, and neither time point. 
The Alcohol Use Disorders Identification Test (AUDIT) was used to assess past-year 
alcohol use with responses provided by self-report at baseline and the one-year postoperative 
visit.  The AUDIT was developed by the World Health Organization and consists of ten 
questions (total score of 0-40) used to identify individuals who display harmful consumption 
patterns of alcohol.107  A score of 8 or higher indicates harmful alcohol use and possible alcohol 
dependence with a score of 20 or higher warranting evaluation for alcohol dependence.107  Thus, 
participants were classified as positive for alcohol use disorder symptoms if their AUDIT score 
was >8.  In addition to the AUDIT score, data from individual questions on frequency of alcohol 
consumption and number of drinks containing alcohol consumed on a typical day were included 
in the analyses.  Only the data from the one-year postoperative visit were used for these alcohol-
related variables. 
Frequency of breakfast consumption was investigated for association with change in 
serum folate since foods commonly consumed at breakfast such as fortified cereals and orange 
juice are good dietary sources of folate and folic acid.50  Participants reported the number of days 
in a usual week that breakfast was consumed at baseline and at one-year follow-up.  Only the 
data from baseline were examined for the study.   One-year postoperative breakfast consumption 
would be less relevant due to the small size of meals and specific diet recommendations for 
individuals after bariatric surgery.  For the statistical analyses, frequency of breakfast 
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consumption reported at baseline was categorized as: 0-2 times per week, 3-5 times per week, or 
6-7 times per week.   
Additional factors that may be associated with folate or iron deficiency are income level 
and education level.  Individuals of lower socioeconomic status are at risk for deficiencies of 
folate and iron due to poor quality diets with decreased intake of micronutrient-rich foods.82,108  
NHANES data have shown a significant association (p<.001) between poverty and lower serum 
folate levels.61  Annual household income was self-reported in LABS-2 at baseline with the 
following categories: <$25,000, $25,000 - $49,999, $50,000 - $74,999, $75,000-$99,999, or 
>$100,000.  Highest education level completed was self-reported at baseline with participants 
selecting from eight categories (less than seventh grade, seventh to less than ninth grade, some 
high school, high school diploma or General Equivalency Degree (GED), some college, other 
post-high school education, college diploma, or graduate or professional degree).   For these 
analyses, the household income categories were condensed to the following: <$25,000, $25,000 - 
$49,999, $50,000 - $74,999, and >$75,000, and the education categories were condensed to: high 
school diploma or GED or less, some college or post-high school education, and college degree 
or greater. 
Participants self-reported the name and frequency of use (daily, weekly, monthly/rarely, 
as needed, or no longer taking) for any prescription medications taken within the past 90 days.  
The list of prescription medications reported by each participant at the one-year postoperative 
visit was reviewed to identify specific medications known to be associated with deficiencies of 
folate or iron.  For example, histamine H2  receptor antagonists can decrease absorption of 
iron.109   
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3.6 STATISTICAL ANALYSIS 
SAS version 9.4 (SAS Institute) and Stata version 14.2 (StataCorp) were used to conduct the 
statistical analyses.  P values of <.05 were considered statistically significant for all analyses.  
Descriptive statistics were calculated for all variables.  For continuous variables, the mean (for 
normally distributed variables) or the median, 25th and 75th percentiles, standard deviation, and 
range were reported.  Frequencies and percentages were reported for categorical variables.  
Normality of variables was assessed using histograms, Q-Q plots, and the Shapiro-Wilk test.  
Distributions of continuous variables were assessed visually for skewness and outliers.  Two-
sample t-tests or analysis of variance (ANOVA) were used to test for differences in means 
between groups for normally distributed continuous variables.  The Mann-Whitney U test or 
Kruskal-Wallis test were used to test differences between, or among, groups for continuous 
variables when not normally distributed.   For categorical variables, the Pearson’s chi-square test 
or Fisher’s exact test were used to test for significant differences between, or among, groups. 
To address the second aim of the study, the change in serum folate and change in serum 
ferritin level from baseline to one year following bariatric surgery were determined for each 
subject.  Scatter plots and box plots were used to visually assess the relationship between 
individual variables and the change in serum folate or ferritin.  Multivariable linear regression 
was used to assess the relationship between type of surgery and mean change in serum folate and 
serum ferritin from baseline to one year following surgery, adjusting for covariates.  To account 
for possible site differences, LABS clinical sites were included as fixed effects.  The LABS 
clinical site with the largest percentage of subjects (32.4%) was used as the reference category of 
site.  The covariates included in the change in serum folate model were: age at surgery, race, 
ethnicity, annual household income, highest level of education completed, baseline BMI, percent 
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weight change from baseline, MVI supplement use on a daily/weekly basis (at neither baseline or 
one-year follow-up, at baseline only, at follow-up only, at both baseline and follow-up), folate 
supplement use on a daily/weekly basis (at neither baseline or one-year follow-up, at baseline 
only, at follow-up only, at both baseline and follow-up), baseline serum folate level, alcohol use 
disorder symptoms at one-year follow-up (as determined by AUDIT score), frequency of alcohol 
consumption reported at one-year follow-up, number of alcoholic beverages consumed on a 
typical day reported at one-year follow-up, and frequency of breakfast consumption reported at 
baseline.  Age at surgery and baseline BMI were centered at their median values.  The same 
variables were adjusted for in the change in serum ferritin model with the following exceptions: 
MVI with minerals supplement use on a daily/weekly basis (at neither baseline or one-year 
follow-up, at baseline only, at follow-up only, at both baseline and follow-up) replaced MVI 
supplement use, iron supplement use on a daily/weekly basis (at neither baseline or one-year 
follow-up, at baseline only, at follow-up only, at both baseline and follow-up) replaced folate 
supplement use, and baseline serum ferritin level replaced baseline serum folate level.  Use of 
histamine H2 receptor antagonist medication reported at the one-year postoperative visit was 
considered in the change in serum ferritin model, and the alcohol use variables at one-year 
postoperatively and frequency of breakfast consumption at baseline were not.  
The prevalence of deficiency of each micronutrient at both baseline and one year after 
surgery was determined for both types of surgery.  Box plots were used to visually assess the 
relationship between each continuous variable and the presence or absence of deficiency.  
Contingency tables with frequencies and prevalence percentages were created for categorical 
variables.  Pearson’s chi-square test or Fisher’s exact test were used to test if the prevalence of 
deficiency differed significantly between, or among, groups.  The Mantel-Haenszel chi-square 
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test was used to test for significant linear trends for ordinal variables.  A test of symmetry was 
conducted to assess change in the distributions of folate and ferritin sufficiency status (deficient, 
within the normal range, or above the normal range/high) from baseline to one year after surgery.  
Multivariable logistic regression was used to assess the relationship between type of surgery and 
presence of ferritin deficiency at one year following surgery, while adjusting for the following 
covariates: age at surgery, race, ethnicity, annual household income, highest level of education 
completed, baseline BMI, ferritin deficiency status at baseline, percent weight change from 
baseline, MVI including minerals supplement use one-year postoperatively, iron supplement use 
one-year postoperatively, and use of histamine H2 receptor antagonist medication one-year 
postoperatively.  As will be discussed in the “Results” section, multivariable logistic regression 
was not conducted for folate deficiency due to a lack of subjects with deficiency at one-year 
follow-up.  
To address the third aim of the study, multivariable linear regression was used to assess 
the association of baseline and post-operative factors with change in serum folate and serum 
ferritin among women who underwent RYGB.  LABS clinical site was included in the model as 
fixed effects.  The same covariates as listed above were examined for association with change 
serum folate and serum ferritin.   
The following process was used for multivariable linear and logistic models.  Simple 
regression models were created to assess the linear relationship between each variable and the 
outcome.  An initial multivariable base model was created that included the demographic 
variables, BMI at baseline, percent weight change from baseline, supplement use variables, and 
LABS clinical site as fixed effects.  Next, a parsimonious model was created which included 
significant variables from the base model, significant variables from the simple regression 
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models using the multiple degree of freedom test for categorical variables, and LABS clinical 
site as fixed effects.  Using stepwise regression, all other variables were then added to the 
parsimonious model stepwise with those variables with p<.05 remaining in the model with the 
exception of race and supplement use variables which were maintained in the models regardless 
of statistical significance.  Race and supplement use are of particular interest due to potential 
confounding by these variables, and the study may have been underpowered to detect a 
significant association due to low prevalence (e.g. African American race) or missing data (e.g. 
supplement use).  For multiple category variables (i.e. supplement use, annual household 
income), all categories of a variable were added stepwise at the same time.  All two-way 
interactions were tested for variables in each final main effects model.  Parameter estimates for 
multivariable linear regression models were determined.  For multivariable logistic regression 
models, point estimates, adjusted odds ratios, and 95% confidence intervals were determined.  
Assumptions were tested for each final model. 
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4.0  RESULTS 
4.1 SUBJECTS 
The study was designed to have 427 subjects with 280 subjects (66%) in the RYGB group and 
147 subjects (34%) in the LAGB group (Figure 6).  However, the final sample was 426 because 
the serum samples for one LAGB subject were hemolyzed and could not be used for analyses so 
this subject was excluded.  Replacement of this subject was not an option because there were no 
other subjects who had undergone LAGB who met the inclusion criteria for the study.   
Demographic and other select characteristics for the subjects are presented in Table 8.  
The median age was 37 years in both surgery groups.  Most subjects, 86.5%, were white while 
10.4% were African American, and 3.1% of subjects reported being of other or multiple races.  
Only, 7.7% of the subjects were Hispanic.  There were no significant differences in the 
distribution of race or ethnicity by surgery.  The distribution of education differed significantly 
by surgical procedure (p=.002).  A larger percentage of subjects having a LAGB, 50.7%, 
compared to those undergoing a RYGB, 32.7%, reported at least a college education.  The 
distribution of household income also differed significantly by surgery (p=.0007).  A larger 
percentage of subjects having a LAGB, 39.5%, compared to those undergoing a RYGB, 22.2%, 
reported an annual household income of $75,000 or more.  Baseline BMI was significantly 
higher (p=.0003) for subjects who underwent a RYGB (median 46.6 kg/m2) compared to LAGB 
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(median 44.3 kg/m2).  The median percent weight change was significantly greater (p<.0001) for 
subjects who had undergone RYGB (median 36.0%) compared to LAGB (median 14.2%).   
At baseline, 50.6% of subjects reported taking a MVI daily, 47.2% reported taking a MVI 
that included minerals daily, 10.9% reported taking an iron supplement either daily or weekly, 
and 2.0% of subjects reported taking a folate supplement daily or weekly.  These percentages 
increased substantially one year after surgery when 75.3% of the subjects reported taking a MVI 
daily, 71.5% reported taking a MVI that included minerals daily, 34.9% reported taking an iron 
supplement either daily or weekly, and 7.7% of subjects reported taking a folate supplement 
daily or weekly.  At baseline, there were no significant differences in distributions of MVI, MVI 
with minerals, iron, or folate supplement use by type of surgery.  The percentage of subjects who 
took an MVI, MVI including minerals, iron, and folate supplement use at one-year follow-up 
differed by surgery (p<.0001, p=.004, p<.0001, and p=.02, respectively).  Subjects who had 
undergone RYGB compared to LAGB were more likely to take a MVI daily (83.8% vs. 58.0%), 
MVI including minerals daily (78.9% vs. 56.5%), iron supplement daily or weekly (46.5% vs. 
11.1%), or a folate supplement daily or weekly (10.0% vs. 3.1%). 
Prior to surgery, 53.7% of subjects reported consuming breakfast six to seven times per 
week, while 13.1% reported consuming breakfast two or less times per week.  The distribution of 
frequency of breakfast consumption did not differ by surgery.  At baseline, a larger percentage of 
subjects who had a LAGB, 5.8%, reported using a histamine H2 receptor antagonist medication 
compared to 1.9% of subjects who underwent RYGB (p=.04).  One year after surgery, the use of 
a histamine H2 receptor antagonist medication did not differ significantly by surgery  
Prior to surgery, 36.8% of subjects reported never drinking alcohol and only three 
subjects (0.7%) reported consuming alcohol four or more times per week.  These percentages 
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were similar after surgery as 37.9% of subjects reported never drinking alcohol and 1.9% of 
subjects reported consuming alcohol four or more times per week.  Frequency of alcohol 
consumption did not differ significantly by surgical procedure at either baseline or one year after 
surgery.  Before surgery, 22.5% of subjects reported drinking three or more alcoholic beverages 
per day on a typical day when drinking.  One year after surgery, this percentage decreased to 
18.5%.  A larger percentage of subjects who underwent RYGB, 24.4%, reported consuming 
three or more alcoholic drinks per day on a typical day when drinking prior to surgery compared 
to 18.9% of subjects who underwent LAGB.  Whereas, one year after surgery, a larger 
percentage of subjects who had undergone LAGB compared to RYGB reported consuming three 
or more alcoholic drinks per day on a typical day when drinking (23.4% vs. 16.1%, respectively).  
For the AUDIT score, 5.4% and 5.9% of subjects received a score indicating harmful alcohol use 
and possible alcohol dependence at baseline and one year after surgery, respectively.  The 
AUDIT score did not differ significantly by surgery at either time point. 
 At the one-year postoperative visit, four subjects reported being pregnant.  Nine subjects 
reported possibly being pregnant.  Pregnancy status did not differ significantly by surgery.  
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Table 8:  Demographic and select characteristics of subjects     
  Total 
(n=426) 
LAGB 
(n=146) 
RYGB 
(n=280) 
p 
Age (years) Median 37 37 37 0.39 
 25th, 75th %ile   31, 41 32, 42 31, 41  
 Range 18-45 18-45 19-45  
 Missing (n, %) 0 (0) 0 (0) 0 (0)  
 n (%) n (%) n (%)  
Race    0.28 
    White 365 (86.5) 128 (89.5) 237 (85.0)  
    Black 44 (10.4) 13 (9.1) 31 (11.1)  
    Other or multiple races 13 (3.1) 2 (1.4) 11 (3.9)  
    Missing 4 (0.9) 3 (2.1) 1 (0.4)  
     
Ethnicity    0.52 
    Hispanic 33 (7.7) 13 (8.9) 20 (7.1)  
    Non-Hispanic 393 (92.3) 133 (91.1) 260 (92.9)  
    Missing 0 (0) 0 (0) 0 (0)  
     
Education    0.002 
    < High school diploma   84 (20.8) 23 (16.7) 61 (22.9)  
    Some college or post-high school   163 (40.3) 45 (32.6) 118 (44.4)  
    > College degree 157 (38.9) 70 (50.7) 87 (32.7)  
    Missing 22 (5.2) 8 (5.5) 14 (5.0)  
     
Household income    0.0007 
    <$25,000 75 (19.0) 19 (14.2) 56 (21.5)  
    $25,000-$49,999  109 (27.6) 26 (19.4) 83 (31.8)  
    $50,000-$74,999 100 (25.3) 36 (26.9) 64 (24.5)  
   > $75,000  111 (28.1) 53 (39.5) 58 (22.2)  
    Missing 31 (7.3) 12 (8.2) 19 (6.8)  
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB: Roux-en-Y gastric bypass; n: 
number of subjects; %ile: percentile 
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Table 8 (continued):  Demographic and select characteristics of subjects 
  Total 
(n=426) 
LAGB 
(n=146) 
RYGB 
(n=280) 
p 
Baseline BMI (kg/m2)a Median 45.9 44.3 46.6 0.0003 
 25th, 75th %ile   42.0, 50.8 41.0, 48.4 42.8, 51.6  
 Range 32.9-74.7 32.9-66.4 35.4-74.7  
 Missing (n, %) 0 (0) 0 (0) 0 (0)  
      
Percent weight change 
from baseline at 1-year 
post-op (%)b 
 
Median 
 
31.4 
 
14.2 
 
36.0 
 
 <.0001 
 25th, 75th %ile 17.9, 37.9 10.2, 19.9 30.7, 40.9  
 Range 58.5% loss 
to 8.6% gain 
53.0% loss 
to 1.4% gain 
58.4% low 
to 8.6% gain 
 
 Missing (n, %)c 4 (0.9) 1 (0.7) 3 (1.1)  
 n (%) n (%) n (%)  
MVI use, baseline    0.41 
    Daily 203 (50.6) 65 (47.8) 138 (52.1)  
    Weekly 37 (9.2) 16 (11.8) 21 (7.9)  
    Monthly/rarely or no current use 161 (40.2) 55 (40.4) 106 (40.0)  
    Missing 25 (5.9) 10 (6.8) 15 (5.4)  
     
MVI use, 1 year post-op    <.0001 
    Daily 290 (75.3) 73 (58.0) 217 (83.8)  
    Weekly 52 (13.5) 27 (21.4) 25 (9.6)  
    Monthly/rarely or no current use 43 (11.2) 26 (20.6) 17 (6.6)  
    Missing 41 (9.6) 20 (13.7) 21 (7.5)  
     
MVI including minerals use, baseline    0.33 
    Daily 180 (47.2) 60 (45.8) 120 (48.0)  
    Weekly 35 (9.2) 16 (12.2) 19 (7.6)  
    Monthly/rarely or no current use 166 (43.6) 55 (42.0) 111 (44.4)  
    Missing  45 (10.6) 15 (10.3) 30 (10.7)  
     
MVI including minerals use, 1 year post-op    0.004 
    Daily 263 (71.5) 69 (56.5) 194 (78.9)  
    Weekly 49 (13.3) 25 (20.5) 24 (9.7)  
    Monthly/rarely or no current use 56 (15.2) 28 (23.0) 28 (11.4)  
    Missing 58 (13.6) 24 (16.4) 34 (12.1)  
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB: Roux-en-Y gastric bypass; n: 
number of subjects; %ile: percentile; BMI: body mass index; post-op: postoperative; MVI: multivitamin 
aCalculated as weight in kilograms divided by height in meters squared. 
bCalculated as 100*(weight at baseline minus weight at 1 year post-op divided by weight at baseline).  
cWeight data were excluded for three subjects in their second or third trimester of pregnancy and one subject 
who was less than six months postpartum.      
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Table 8 (continued):  Demographic and select characteristics of subjects 
 Total 
(n=426) 
LAGB 
(n=146) 
RYGB 
(n=280) 
p 
 n (%) n (%) n (%)  
Iron supplement use, baseline    0.17 
    Daily or weekly 44 (10.9) 11 (8.0) 33 (12.4)  
    Monthly/rarely or no current use 359 (89.1) 127 (92.0) 232 (87.6)  
    Missing 23 (5.4) 8 (5.5) 15 (5.4)  
     
Iron supplement use, 1 year post-op    <.0001 
    Daily or weekly 134 (34.9) 14 (11.1) 120 (46.5)  
    Monthly/rarely or no current use 250 (65.1) 112 (88.9) 138 (53.5)  
    Missing 42 (9.9) 20 (13.7) 22 (7.9)  
     
Folate supplement use, baseline    0.72 
    Daily or weekly 8 (2.0) 2 (1.4) 6 (2.3)  
    Monthly/rarely or no current use 396 (98.0) 136 (98.6) 260 (97.7)  
    Missing 22 (5.2) 8 (5.5) 14 (5.0)  
     
Folate supplement use, 1 year post-op    0.02 
    Daily or weekly 30 (7.7) 4 (3.1) 26 (10.0)  
    Monthly/rarely or no current use  359 (92.3) 124 (96.9) 235 (90.0)  
    Missing 37 (8.7) 18 (12.3) 19 (6.8)  
     
Breakfast consumption, prior to surgery    0.83 
    0-2 times/week 53 (13.1) 17 (12.3) 36 (13.5)  
    3-5 times/week 134 (33.2) 44 (31.9) 90 (33.8)  
    6-7 times/week 217 (53.7) 77 (55.8) 140 (52.6)  
    Missing 22 (5.2) 8 (5.5) 14 (5.0)  
     
Use of a histamine H2 receptor antagonist 
medication, baseline   
    
0.04 
    Yes 13 (3.2) 8 (5.8) 5 (1.9)  
    No 389 (96.8) 129 (94.2) 260 (98.1)  
    Missing  24 (5.6) 9 (6.2) 15 (5.4)  
     
Use of a histamine H2 receptor antagonist 
medication, 1 year post-op   
    
0.21 
    Yes 27 (7.0) 6 (4.7) 21 (8.1)  
    No 359 (93.0) 122 (95.3) 237 (91.9)  
    Missing  40 (9.4) 18 (12.3) 22 (7.9)  
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB: Roux-en-Y gastric bypass;  
n: number of subjects; post-op: postoperative 
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Table 8 (continued):  Demographic and select characteristics of subjects 
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB: Roux-en-Y gastric bypass;  
n: number of subjects; post-op: postoperative 
 
 
 
 Total 
(n=426) 
LAGB 
(n=146) 
RYGB 
(n=280) 
p 
 n (%) n (%) n (%)  
Frequency of alcohol consumption, baseline    0.43 
    Never 149 (36.8) 46 (33.1) 103 (38.7)  
    <2-4 times/month 232 (57.3) 84 (60.4) 148 (55.6)  
    2-3 times/week 21 (5.2) 7 (5.0) 14 (5.3)  
    >4 times/week 3 (0.7) 2 (1.5) 1 (0.4)  
    Missing 21 (4.9) 7 (4.8) 14 (5.0)  
     
Frequency of alcohol consumption, 1 year 
post-op 
   0.13 
    Never 142 (37.9) 37 (29.8) 105 (41.8)  
    <2-4 times/month 208 (55.4) 77 (62.1) 131 (52.2)  
    2-3 times/week 18 (4.8) 7 (5.7) 11 (4.4)  
    >4 times/week 7 (1.9) 3 (2.4) 4 (1.6)  
    Missing 51 (12.0) 22 (15.1) 29 (10.4)  
     
Number of alcoholic drinks consumed on a 
typical day of drinking, baseline 
   0.04 
    None/not applicable 150 (37.1) 46 (33.3) 104 (39.1)  
    1-2 drinks/day 163 (40.4) 66 (47.8) 97 (36.5)  
    3-6 drinks/day 83 (20.5) 26 (18.9) 57 (21.4)  
    > 7 drinks/day 8 (2.0) 0 (0) 8 (3.0)  
    Missing 22 (5.2) 8 (5.5) 14 (5.0)  
     
Number of alcoholic drinks consumed on a 
typical day of drinking, 1 year post-op 
   0.07 
    None/not applicable 142 (38.2) 39 (31.4) 103 (41.5)  
    1-2 drinks/day 161 (43.3) 56 (45.2) 105 (42.3)  
    3-6 drinks/day 66 (17.7) 29 (23.4) 37 (14.9)  
    > 7 drinks/day 3 (0.8) 0 (0) 3 (1.2)  
    Missing 54 (12.7) 22 (15.1) 32 (11.4)  
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Table 8 (continued):  Demographic and select characteristics of subjects 
 Total 
(n=426) 
LAGB 
(n=146) 
RYGB 
(n=280) 
p 
 n (%) n (%) n (%)  
Alcohol use disorder symptoms, baselined    0.47 
    Yes 22 (5.4) 6 (4.3) 16 (6.0)  
    No 383 (94.6) 133 (95.7) 250 (94.0)  
    Missing 21 (4.9) 7 (4.8) 14 (5.0)  
     
Alcohol use disorder symptoms, 1 year post-opd    0.55 
    Yes 22 (5.9) 6 (4.8) 16 (6.4)  
    No 352 (94.1) 118 (95.2) 234 (93.6)  
    Missing 52 (12.2) 22 (15.1) 30 (10.7)  
     
Pregnancy status, 1 year post-op     1.00 
    Pregnant 4 (0.9) 1 (0.7) 3 (1.1)  
    Possibly pregnant 9 (2.1) 3 (2.0) 6 (2.1)  
    Not pregnant 413 (97.0) 142 (97.3) 271 (96.8)  
    Missing 0 (0) 0 (0) 0 (0)  
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB: Roux-en-Y gastric bypass;  
n: number of subjects; post-op: postoperative   
dBased on score on the Alcohol Use Disorders Identification Test (AUDIT).  An AUDIT score > 8 
indicates harmful alcohol use and possible alcohol dependence.       
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4.2 FOLATE 
4.2.1 Serum folate levels at baseline and follow-up and change in serum folate  
The Heinz Nutrition Laboratory was unable to determine either a preoperative or postoperative 
serum folate level for 13 subjects, so the sample size for the folate analyses was 413 (272 
RYGB, 141 LAGB).  Table 9 presents descriptive statistics for baseline serum folate by type of 
surgery.  The median values at baseline for subjects who underwent LAGB and RYGB were 
27.2 ng/mL (range: 5.2-67.9 ng/mL) and 23.0 ng/mL (range: 2.4-65.9 ng/mL), respectively.  The 
normal range for serum folate for adult females is 5-25 ng/mL,55 and deficiency has been defined 
as serum folate <3 ng/mL for adult females.56,57  For this analysis, a serum folate level of <3 
ng/mL was considered below the normal range (deficient), a serum folate in the range of 3-25 
ng/mL was considered within the normal range, and a serum folate level >25 ng/mL was 
considered above the normal range (high).   
 
Table 9:  Serum folate at baseline 
 Mean 
(ng/mL) 
SD 25th %ile 
(ng/mL) 
Median 
(ng/mL) 
75th %ile 
(ng/mL) 
Range 
(ng/mL) 
Below 
normal 
range:  
n (%) 
Within 
normal 
range:  
n (%) 
Above 
normal 
range: 
 n (%) 
LAGB 
(n=141) 
27.2 11.6 18.4 26.4 36.2 5.2-67.9 0  
 (0%) 
64 
(45.4%) 
77 
(54.6%) 
RYGB 
(n=272) 
23.0 12.2 12.0 22.2 31.1 2.4-65.9 1 
(0.4%) 
159 
(58.4%) 
112 
(41.2%) 
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB: Roux-en-Y gastric bypass;  
n: number of subjects; SD: standard deviation; %ile: percentile 
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Table 10 presents descriptive statistics for serum folate at the one-year postoperative visit 
by surgery.  Median values for subjects who underwent LAGB and RYGB were 22.3 ng/mL 
(range: 2.4-57.8 ng/mL) and 26.0 ng/mL (range: 1.25-74.0 ng/mL), respectively.   
 
Table 10:  Serum folate at the one-year postoperative visit 
 Median 
(ng/mL) 
25th %ile 
(ng/mL) 
75th %ile 
(ng/mL) 
Range 
(ng/mL) 
Below 
normal 
range: 
n (%) 
Within 
normal 
range: 
 n (%) 
Above 
normal 
range: 
n (%) 
LAGB 
(n=141) 
22.3 10.9 34.3 2.4-57.8 1 (0.7%) 78 (55.3%) 62 (44.0%) 
RYGB 
(n=272) 
26.0 12.1 37.0 1.25-74.0 3 (1.1%) 125 (46.0%) 144 (52.9%) 
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB: Roux-en-Y gastric bypass;  
n: number of subjects;  %ile: percentile 
 
 
 
The change in serum folate from baseline to one year following surgery was determined 
for all subjects by subtracting the baseline serum level from the one-year postoperative visit 
serum level.  A negative value indicates a decrease in serum folate from baseline to the one-year 
post-operative visit.  Descriptive statistics are presented in Table 11.  Mean change for subjects 
who underwent LAGB was a decrease of 4.3 ng/mL with a range from a decrease of 45.7 ng/mL 
to an increase of 40.1 ng/mL.  For subjects who underwent RYGB, mean change was an increase 
of 2.8 ng/mL with a range from a decrease of 34.3 ng/ml to an increase of 47.9 ng/mL.   
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Table 11:  Change in serum folate level from baseline to the one-year postoperative visit 
 Mean 
(ng/mL) 
SD 25th %ile 
(ng/mL) 
Median 
(ng/mL) 
75th %ile 
(ng/mL) 
Range 
(ng/mL) 
LAGB (n=141) -4.3 14.8 -13.4 -4.4 5.7 -45.7 to 40.1 
RYGB (n=272) 2.8 15.9 -6.8 1.5 11.4 -34.3 to 47.9 
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB: Roux-en-Y gastric bypass; 
n: number of subjects; SD: standard deviation; %ile: percentile 
 
 
4.2.1.1 Investigation of high serum folate levels 
Due to the large percentage of subjects with serum folate levels above the normal range at both 
baseline and one year following bariatric surgery, analyses were conducted to determine if an 
association existed between serum levels and MVI or folate supplement use or fasting status at 
the time of blood draw.   
Serum folate levels and MVI or folate supplement use 
MVI supplements commonly contain folic acid.  For the purpose of these analyses, “MVI or 
folate supplement use” was defined as daily or weekly reported use of MVI and/or folate 
supplements.  Reported frequency of use of less than weekly was classified as no MVI or folate 
supplement use.  Box plots of serum folate levels and reported MVI or folate supplement use at 
baseline and the one-year postoperative visit are presented in Figure 7 and Figure 8.  The box 
plots at both time points indicated higher serum folate levels for those subjects who reported 
taking an MVI and/or folate supplement on a daily or weekly basis.  The differences in baseline 
mean serum folate levels and one-year follow-up median serum folate levels based on MVI or 
folate supplement use were significant (p<.0001 for both time points).   
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Abbreviations: MVI: multivitamin 
 
Figure 7:  Box plot to assess baseline serum folate levels by MVI and/or folate supplement  
use reported at baseline 
 
 
 
 
Abbreviations: MVI: multivitamin 
Figure 8:  Box plot to assess one-year postoperative serum folate levels by MVI and/or 
folate supplement use reported at the one-year postoperative visit 
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Serum folate levels and fasting status 
Fasting is not required for serum folate testing; however, an eight-hour fast is often 
recommended.55,57  The inclusion criteria did not require fasting serum samples.  The fasting 
status of each participant was recorded by LABS personnel for both the baseline and one-year 
postoperative visit blood draws.  “Fasting” was defined as fasting for eight or more hours prior to 
the blood draw and “non-fasting” was defined as no fasting or fasting for less than eight hours.  
Box plots and statistical analyses were conducted to determine if an association existed between 
fasting status and serum folate levels.   
For the baseline samples, 85.7% of the samples from which serum folate levels were 
determined were from fasting samples.  For the one-year postoperative serum folate levels, 
78.2% were obtained from fasting samples.  The box plots (Figure 9 and Figure 10) and 
statistical testing did not suggest an association between fasting status and serum folate levels at 
baseline (p=.07) or the one-year postoperative visit (p=.55). 
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Figure 9:  Box plot to assess serum folate levels at baseline by fasting status 
 
 
Figure 10:  Box plot to assess serum folate levels at one-year postoperative visit by fasting 
status 
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4.2.2 Association of bariatric surgery and change in serum folate 
Plots of individual covariates versus change in serum folate are presented in Figure 11 and 
Figure 12.   
 
 
Figure 11:  Scatter plots of continuous variables and change in serum folate 
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Abbreviations: BMI: body mass index 
 
 
 
Figure 11 (continued):  Scatter plots of continuous variables and change in serum folate 
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Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB: Roux-en-Y gastric bypass 
 
 
 
 
Figure 12:  Box plots of categorical variables and change in serum folate 
 
77 
 
 
 
Figure 12 (continued):  Box plots of categorical variables and change in serum folate 
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Abbreviations: MVI: multivitamin 
 
Figure 12 (continued):  Box plots of categorical variables and change in serum folate 
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Figure 12 (continued):  Box plots of categorical variables and change in serum folate 
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Figure 12 (continued):  Box plots of categorical variables and change in serum folate 
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Figure 12 (continued):  Box plots of categorical variables and change in serum folate 
 
Table 12 presents the parameter estimates, p-values, and model statistics from the base 
multivariable model of the association of bariatric surgery and change in serum folate.  The 
reduction in sample size for the model compared to the total sample size (n=413) is due to 
missing data for individual variables in the model.   
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Table 12:  Multivariable linear regression for change in serum folate – Base Model (n=338) 
P-value for the model:  0.0001 
Adjusted R-squared: 0.11 
Variable Parameter 
Estimate 
Standard 
Error 
p 
Intercept -5.9 4.7 0.22 
RYGB (vs. LAGB) 11.1 3.2 0.001 
Age at surgery (centered at the median) 0.1 0.2 0.44 
Black race (vs. white) -2.5 3.2 0.43 
Other race or multiple races (vs. white) 0.4 5.1 0.93 
Hispanic ethnicity (vs. non-Hispanic) -2.7 3.8 0.48 
Some college education (vs. high school diploma or less) 3.4 2.4 0.17 
College degree or higher (vs. high school diploma or less) 5.9 2.6 0.02 
Annual household income: $25,000-$49,999 (vs. <$25,000) -0.8 2.7 0.76 
Annual household income: $50,000-$74,999 (vs. <$25,000) -4.7 2.8 0.10 
Annual household income: >$75,000 (vs. <$25,000) 0.6 2.9 0.83 
Baseline BMI (centered at the median) -0.01 0.1 0.92 
Percent weight change from baseline -0.2 0.1 0.09 
Daily/weekly MVI use at baseline only (vs. no daily/weekly 
use at baseline or follow-up) 
-1.6 6.0 0.79 
Daily/weekly MVI use at follow-up only (vs. no daily/weekly 
use at baseline or follow-up) 
4.7 3.9 0.23 
Daily/weekly MVI use baseline and follow-up (vs. no 
daily/weekly use at baseline or follow-up) 
0.7 3.7 0.84 
Daily/weekly folate supplement use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
-8.0 8.2 0.32 
Daily/weekly folate supplement use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
8.3 3.6 0.02 
Daily/weekly folate supplement use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
-12.6 11.5 0.28 
Abbreviations: RYGB: Roux-en-Y gastric bypass; LAGB: laparoscopic adjustable gastric banding;  
BMI: body mass index; MVI: multivitamin 
 
 
 
Table 13 presents the parsimonious multivariable model.  College degree or higher was 
removed from the model based on the results of the multiple degree of freedom test for education 
(p=.40). 
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Table 13:  Multivariable linear regression for change in serum folate – Parsimonious 
Model (n=354) 
 
P-value for the model:  <.0001 
Adjusted R-squared: 0.10 
Variable Parameter 
Estimate 
Standard 
Error 
p 
Intercept -5.7 3.5 0.11 
RYGB (vs. LAGB) 6.5 2.1 0.002 
Black race (vs. white) -2.7 3.1 0.38 
Daily/weekly MVI use at baseline only (vs. no daily/weekly 
use at baseline or follow-up) 
-2.2 5.8 0.70 
Daily/weekly MVI use at follow-up only (vs. no daily/weekly 
use at baseline or follow-up) 
4.1 3.7 0.27 
Daily/weekly MVI use at baseline and follow-up (vs. no 
daily/weekly use at baseline or follow-up) 
0.1 3.6 0.97 
Daily/weekly folate supplement use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
-5.6 8.1 0.47 
Daily/weekly folate supplement use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
8.3 3.5 0.02 
Daily/weekly folate supplement use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
-14.4 9.4 0.12 
Abbreviations: RYGB: Roux-en-Y gastric bypass; LAGB: laparoscopic adjustable gastric banding 
 
  
Only baseline serum folate was significant when added stepwise to the parsimonious 
model.  The final model is presented in Table 14.  No significant interactions were identified in 
the final main effects model.  The final model was tested for the assumptions of multivariable 
linear regression with no violations identified.  The residuals were normally distributed, there 
was no violation of linearity or homoscedasticity, and no evidence of collinearity among the 
independent variables. 
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Table 14:  Final Model: Association of bariatric surgery and change in serum folate based 
on multivariable linear regression (n=354) 
 
P-value for the model:  <.0001 
Adjusted R-squared: 0.28 
Variable Parameter 
Estimate 
Standard 
Error 
p 
Intercept 8.4 3.3 0.01 
RYGB (vs. LAGB) 3.0 1.7 0.08 
Black race (vs. white) -1.5 2.5 0.56 
Daily/weekly MVI use at baseline only (vs. no daily/weekly 
use at baseline or follow-up) 
-3.4 5.0 0.50 
Daily/weekly MVI use at follow-up only (vs. no daily/weekly 
use at baseline or follow-up) 
7.1 3.3 0.03 
Daily/weekly MVI use at baseline and follow-up (vs. no 
daily/weekly use at baseline or follow-up) 
6.6 3.3 0.04 
Daily/weekly folate supplement use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
-9.1 7.2 0.20 
Daily/weekly folate supplement use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
4.8 3.0 0.12 
Daily/weekly folate supplement use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
-16.5 8.2 0.045 
Baseline serum folate -0.7 0.1 <.0001 
Abbreviations: RYGB: Roux-en-Y gastric bypass; LAGB: laparoscopic adjustable gastric banding: MVI: 
multivitamin 
 
 
Type of bariatric surgery was not significantly associated with change in serum folate 
from baseline to one year after surgery when controlling for the other variables in the model 
(Black race, daily/weekly MVI use, daily/weekly folate supplement use, and baseline serum 
folate level).  The overall clinical site effect was tested using the multiple degree of freedom test 
and was not significant (p=.55); therefore, clinical sites were not included in the final model.     
4.2.3 Association of bariatric surgery and folate deficiency one year after surgery 
The subjects’ serum folate levels at baseline and one-year follow-up were classified as deficient 
(<3 ng/mL), within the normal range (3-25 ng/mL), and above the normal range (high) (>25 
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ng/mL).  Table 15 shows deficiency status by surgery separately for baseline and one-year 
follow-up.  Prior to surgery, no subjects who underwent LAGB and only one subject (0.4%) who 
underwent RYGB were deficient in folate.  One year following surgery, only one subject (0.7%) 
who underwent LAGB and three subjects (1.1%) who underwent RYGB were folate-deficient.  
The prevalence of folate deficiency at baseline and one year following surgery did not differ 
significantly by surgery (p=1.0 for both time points).  Per self-report, four subjects were pregnant 
at the one-year postoperative follow-up visit.  None of these subjects were deficient in folate at 
baseline or at one-year follow-up.  
 
Table 15:  Folate deficiency status by surgery at baseline and one-year follow-up 
 LAGB 
(n=141) 
RYGB 
(n=272) 
P 
 n (%) n (%)  
At baseline:    
    Deficient 0 (0) 1 (0.4) 1.00 
    Not-deficient  141 (100.0) 271 (99.6)  
    
At 1-year follow-up:    
    Deficient 1 (0.7) 3 (1.1) 1.00 
    Not-deficient 140 (99.3) 269 (98.9)  
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB:  
Roux-en-Y gastric bypass; n: number of subjects 
 
 
Table 16 (LABG group) and Table 17 (RYGB group) present folate status (deficient, 
within the normal range, or high) at baseline and one-year follow-up.  In the LAGB group, one 
subject (1.6%) whose serum folate was in the normal range at baseline was deficient one year 
after surgery.  Overall, the distributions at baseline and follow-up did not change significantly 
(p=.18).  For the RYGB group, three subjects (1.9%) who were within the normal range prior to 
RYGB were deficient one year after surgery.  The overall distributions changed from pre-op to 
post-op such that a greater percentage of subjects went from within the normal range to high 
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rather than changing from within the normal range to deficient or from high to within the normal 
range (p=.01).  Prior to surgery, 54.6 % of subjects who underwent LAGB and 41.2% of subjects 
who underwent RYGB had high serum folate levels.  One year after surgery, 44.0% of subjects 
who underwent LAGB and 52.9% of subjects who underwent RYGB had high serum folate 
levels.   
 
Table 16:  Folate sufficiency status at baseline and one-year postoperative for the LAGB 
group 
 
 Folate Status at 1-Year Follow-up (LAGB) 
Folate Status at 
Baseline 
(LAGB) 
 
 
Deficient 
 
 
Normal 
Range 
 
 
High 
Total 
(frequency, 
percent) 
Deficient 
(frequency, row 
percentage) 
0 
0% 
0 
0% 
0 
0% 
0 
0% 
Normal range 
(frequency, row 
percentage) 
1 
1.6% 
42 
65.6% 
21 
32.8% 
64 
45.4% 
High 
(frequency, row 
percentage) 
0 
0% 
36 
46.8% 
41 
53.2% 
77 
54.6% 
Total 
(frequency, 
percentage) 
1 
0.7% 
78 
55.3% 
62 
44.0% 
141 
100% 
Abbreviations: LAGB: laparoscopic adjustable gastric banding 
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Table 17:  Folate sufficiency status at baseline and one-year postoperative for the RYGB 
group 
 
 Folate Status at 1-Year Follow-up (RYGB) 
Folate Status at 
Baseline 
(RYGB) 
 
 
Deficient 
 
 
Normal 
Range 
 
 
High 
Total 
(frequency, 
percent) 
Deficient 
(frequency, row 
percentage) 
0 
0% 
1 
100% 
0 
0% 
1 
0.4% 
Normal range 
(frequency, row 
percentage) 
3 
1.9% 
93 
58.5% 
63 
39.6% 
159 
58.4% 
High 
(frequency, row 
percentage) 
0 
0% 
31 
27.7% 
81 
72.3% 
112 
41.2% 
Total 
(frequency, 
percentage) 
3 
1.1% 
125 
46.0% 
144 
52.9% 
272 
100% 
Abbreviations: RYGB: Roux-en-Y gastric bypass 
 
In total, only four subjects (1.0%) were deficient in folate one year after bariatric surgery.  
Due to the low prevalence of folate deficiency, further analysis using multivariable logistic 
regression to determine if there was an association between bariatric surgery and folate 
deficiency was deemed unnecessary.  
4.2.4 Factors associated with change in serum folate from baseline to one year after 
RYGB 
Plots of individual covariates versus change in serum folate for subjects who had undergone 
RYGB are presented in Figure 13 and Figure 14.  
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Abbreviations: BMI: body mass index 
 
 
 
Figure 13:  Scatter plots of continuous variables and change in serum folate after RYGB 
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Figure 13 (continued):  Scatter plots of continuous variables and change in serum folate 
after RYGB 
 
 
 
 
Figure 14:  Box plots of categorical variables and change in serum folate after RYGB 
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Figure 14 (continued): Box plots of categorical variables and change in serum folate after 
RYGB 
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Abbreviations: MVI: multivitamin 
 
 
Figure 14 (continued): Box plots of categorical variables and change in serum folate after 
RYGB 
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Figure 14 (continued): Box plots of categorical variables and change in serum folate after 
RYGB 
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Figure 14 (continued): Box plots of categorical variables and change in serum folate after 
RYGB 
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Figure 14 (continued): Box plots of categorical variables and change in serum folate after 
RYGB 
 
 
Parameter estimates, p-values, and model statistics for the base multivariable model of 
factors associated with change in serum folate among women who had undergone RYGB are 
presented in Table 18.  The reduction in sample size for the model compared to total sample size 
(n=272) is due to missing data for individual variables. 
 
  
 
 
 
 
 
 
 
 
 
 
95 
Table 18:  Multivariable linear regression model for change in serum folate after RYGB – 
Base Model (n=228) 
 
P-value for the model:  0.10 
Adjusted R-squared: 0.04 
Variable Parameter 
Estimate 
Standard 
Error 
p 
Intercept -1.0 9.2 0.91 
Age at surgery (centered at the median) 0.1 0.2 0.58 
Black race (vs. white) -3.0 3.8 0.43 
Other race or multiple races (vs. white) -1.7 6.0 0.78 
Hispanic ethnicity (vs. non-Hispanic) -4.0 5.1 0.44 
Some college education (vs. high school diploma or less) 2.6 2.9 0.38 
College degree or higher (vs. high school diploma or less) 5.9 3.3 0.07 
Annual household income: $25,000-$49,999 (vs. <$25,000) -0.8 3.2 0.80 
Annual household income: $50,000-$74,999 (vs. <$25,000) -2.9 3.6 0.43 
Annual household income: >$75,000 (vs. <$25,000) -0.7 3.7 0.85 
Baseline BMI (centered at the median) 0.1 0.2 0.70 
Percent weight change from baseline -0.2 0.2 0.30 
Daily/weekly MVI use at baseline only (vs. no daily/weekly 
use at baseline or follow-up) 
-4.0 11.1 0.72 
Daily/weekly MVI use at follow-up only (vs. no daily/weekly 
use at baseline or follow-up) 
10.5 6.5 0.11 
Daily/weekly MVI use at baseline and follow-up (vs. no 
daily/weekly use at baseline or follow-up) 
7.6 6.4 0.24 
Daily/weekly folate supplement use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
-0.9 10.1 0.93 
Daily/weekly folate supplement use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
8.2 3.9 0.04 
Daily/weekly folate supplement use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
-13.7 12.0 0.25 
Abbreviations: BMI: body mass index; MVI: multivitamin 
 
 
Only daily/weekly folate supplement use at follow-up only was significant in the base 
model.  No variables were significant in the simple regression or multiple degree of freedom 
tests.  Table 19 shows the parsimonious multivariable model.   
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Table 19:  Multivariable linear regression model for change in serum folate after RYGB – 
Parsimonious Model (n=238) 
 
P-value for the model:  0.003 
Adjusted R-squared: 0.08 
Variable Parameter 
Estimate 
Standard 
Error 
p 
Intercept -3.2 6.0 0.60 
Black race (vs. white) -2.7 3.5 0.44 
Daily/weekly MVI use at baseline only (vs. no daily/weekly 
use at baseline or follow-up) 
-4.0 10.4 0.70 
Daily/weekly MVI use at follow-up only (vs. no daily/weekly 
use at baseline or follow-up) 
9.0 5.9 0.13 
Daily/weekly MVI use at baseline and follow-up (vs. no 
daily/weekly use at baseline or follow-up) 
6.3 5.8 0.28 
Daily/weekly folate supplement use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
1.3 9.7 0.89 
Daily/weekly folate supplement use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
9.0 3.8 0.02 
Daily/weekly folate supplement use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
-11.6 9.6 0.23 
Abbreviations: MVI: multivitamin 
 
 
 
When all covariates were added to the model stepwise, the only variable that had a p<.05 
was baseline serum folate.  The final model is presented in Table 20.  No significant interactions 
were identified in the final main effects model.  The final model met the assumptions of 
multivariable linear regression.  The residuals for the model were normally distributed.  There 
was no evidence of heteroscedasticity, non-linearity between the dependent and independent 
variables, or collinearity among the independent variables in the final model.   
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Table 20:  Final Model:  Factors associated with change in serum folate from baseline to 
one year following RYGB among women of childbearing age (n=238) 
 
P-value for the model:  <.0001 
Adjusted R-squared: 0.24 
Variable Parameter 
Estimate 
Standard 
Error 
p 
Intercept 6.9 5.3 0.20 
Black race (vs. white) -1.7 3.0 0.58 
Daily/weekly MVI use at baseline only (vs. no daily/weekly 
use at baseline or follow-up) 
-4.7 9.1 0.60 
Daily/weekly MVI use at follow-up only (vs. no daily/weekly 
use at baseline or follow-up) 
10.9 5.3 0.04 
Daily/weekly MVI use at baseline and follow-up (vs. no 
daily/weekly use at baseline or follow-up) 
12.3 5.3 0.02 
Daily/weekly folate supplement use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
-5.9 8.7 0.50 
Daily/weekly folate supplement use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
4.5 3.3 0.18 
Daily/weekly folate supplement use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
-17.5 8.4 0.04 
Baseline serum folate -0.7 0.1 <.0001 
Abbreviations: MVI: multivitamin 
 
 
 
For women of childbearing age who had undergone RYGB, daily/weekly MVI use at 
follow-up only and daily/weekly MVI use at both baseline and follow-up were negative 
confounders of the relationship between RYGB and change in serum folate.  Daily/weekly MVI 
use at follow-up only was associated, on average, with a 10.9 ng/mL greater change in serum 
folate compared to subjects who reported not taking a MVI on a daily or weekly basis at either 
baseline or one-year follow-up (p=.04), after adjusting for the other variables in the model.  
Daily/weekly MVI use at both baseline and follow-up was associated, on average, with a 12.3 
ng/mL greater change in serum folate compared to subjects who reported not taking a MVI on a 
daily or weekly basis at either baseline or one-year follow-up (p=.02), after adjusting for the 
other variables in the model.  Daily/weekly use of a folate supplement at both baseline and 
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follow-up was associated, on average, with a 17.5 ng/mL lower change in serum folate compared 
to subjects who reported not taking a folate supplements on a daily or weekly basis at either 
baseline or one-year follow-up (p=.04), after adjusting for the other variables in the model.   
Folate supplements are not standardly recommended after RYGB; and therefore, folate 
supplement use would not be considered a confounder of the relationship.  Baseline serum folate 
level was significantly (p<.0001) associated with change in serum folate, after adjusting for the 
other covariates in the model.  The overall clinical site effect was tested using the multiple 
degree of freedom test and was not significant (p=.31); therefore, clinical sites were not included 
in the final model.     
4.3 FERRITIN 
4.3.1 Serum ferritin levels at baseline and follow-up and change in serum ferritin 
Baseline and one-year postoperative serum ferritin levels were available for all 426 subjects.  
Table 21 presents descriptive statistics for baseline serum ferritin by surgery.  Median values for 
LAGB and RYGB are 51.0 ng/mL and 59.0 ng/mL, respectively, with ranges from 2.0-441.0 
ng/mL among women who underwent LAGB and 1.5-320.0 ng/mL among those who underwent 
RYGB.  The normal range for serum ferritin for adult females is 10-150 ng/mL,55 and iron 
deficiency has been defined as <15 ng/mL for adult females.79,81  A serum ferritin level of <15 
ng/mL was considered below the normal range (deficient), a serum ferritin level between 15-150 
ng/mL was considered within the normal range, and a level >150 ng/mL was classified as above 
the normal range (high).   
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Table 21:  Serum ferritin at baseline 
 Median 
(ng/mL) 
25th 
%ile 
(ng/mL) 
75th 
%ile 
(ng/mL) 
Range 
(ng/mL) 
Below the 
normal 
range: n (%) 
Within the 
normal 
range: n (%) 
Above the 
normal 
range: n (%) 
LAGB 
(n=146) 
51.0 26.0 92.0 2.0-441.0 12 (8.2%) 120 (82.2%) 14 (9.6%) 
RYGB 
(n=280) 
59.0 33.0 95.5 1.5-320.0 19 (6.8%) 231 (82.5%) 30 (10.7%) 
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB: Roux-en-Y gastric bypass; n: 
number of subjects; %ile: percentile 
 
 
Table 22 presents descriptive statistics for serum ferritin at the one-year postoperative 
visit by surgery.  Median values for LAGB and RYGB were 46.0 ng/mL and 43.0 ng/mL, 
respectively, with ranges from 1.1-464.0 ng/mL among women who underwent LAGB and 1.8-
435.0 ng/mL among those who underwent RYGB surgery.   
 
Table 22:  Serum ferritin at the one-year postoperative visit 
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB: Roux-en-Y gastric bypass; n: 
number of subjects; %ile: percentile 
 
 
 
The change in serum ferritin was calculated by subtracting the baseline serum level from 
the one-year postoperative visit serum level.  A negative value indicates a decrease in ferritin 
level from baseline to one-year after surgery.  Descriptive statistics are presented in Table 23.  
The mean change for subjects who underwent LAGB was a decrease of 3.8 ng/mL with a range 
from a decrease of 156.0 ng/mL to an increase of 130.0 ng/mL.  For subjects who underwent 
 Median 
(ng/mL) 
25th 
%ile 
(ng/mL) 
75th 
%ile 
(ng/mL) 
Range 
(ng/mL) 
Below the 
normal 
range: n (%) 
Within the 
normal range: 
n (%) 
Above the 
normal 
range: n (%) 
LAGB 
(n=146) 
46.0 26.0 84.0 1.1–464.0 20 (13.7%) 108 (74.0%) 18 (12.3%) 
RYGB 
(n=280) 
43.0 18.0 83.5 1.8–435.0 61 (21.8%) 194 (69.3%) 25 (8.9%) 
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RYGB, the mean change was a decrease of 11.9 ng/mL with a range from a decrease of 192.0 
ng/mL to an increase of 249.0 ng/mL 
 
Table 23:  Change in serum ferritin level from baseline to the one-year postoperative visit 
 Mean 
(ng/mL) 
SD 25th %ile 
(ng/mL) 
Median 
(ng/mL) 
75th %ile 
(ng/mL) 
Range 
(ng/mL) 
LAGB (n=146) -3.8 38.5 -20.0 -4.0 12.0 -156.0 to 130.0 
RYGB (n=280) -11.9 51.3 -35.0 -12.0 9.0 -192.0 to 249.0 
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB: Roux-en-Y gastric bypass; n: 
number of subjects; SD: standard deviation; %ile: percentile 
 
 
4.3.2 Association of bariatric surgery and change in serum ferritin 
Plots of individual covariates versus change in serum ferritin are presented in Figure 15 and 
Figure 16.   
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Abbreviations:  BMI: body mass index 
Figure 15:  Scatter plots of continuous variables and change in serum ferritin    
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Figure 15 (continued):  Scatter plots of continuous variables and change in serum ferritin    
 
 
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB: Roux-en-Y gastric bypass 
Figure 16:  Box plots of categorical variables and change in serum ferritin 
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Figure 16 (continued):  Box plots of categorical variables and change in serum ferritin 
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Figure 16 (continued):  Box plots of categorical variables and change in serum ferritin 
 
105 
 
Abbreviations: MVI: multivitamin 
 
 
 
Figure 16 (continued):  Box plots of categorical variables and change in serum ferritin 
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Figure 16 (continued):  Box plots of categorical variables and change in serum ferritin 
 
Parameter estimates, p-values, and model statistics from the base multivariable linear 
regression model for association of bariatric surgery with change in serum ferritin are presented 
in Table 24.  The reduction in sample size for the model (compared to n=426) is due to missing 
data for individual variables. 
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Table 24:  Multivariable linear regression for change in serum ferritin – Base Model  
(n=313) 
 
P-value for the model:  0.01 
Adjusted R-squared: 0.07 
Variable Parameter 
Estimate 
Standard 
Error 
p 
Intercept -34.1 14.1 0.02 
RYGB (vs. LAGB) -38.0 10.2 0.0002 
Age at surgery (centered at the median) 0.1 0.5 0.79 
Black race (vs. white) -10.6 9.9 0.28 
Other race or multiple races (vs. white) -5.5 16.3 0.73 
Hispanic ethnicity (vs. non-Hispanic) 1.2 11.8 0.92 
Some college education (vs. high school diploma or less) -0.4 7.8 0.96 
College degree or higher (vs. high school diploma or less) -5.9 8.2 0.47 
Annual household income: $25,000-$49,999 (vs. <$25,000) 18.3 8.4 0.03 
Annual household income: $50,000-$74,999 (vs. <$25,000) -4.0 8.9 0.65 
Annual household income: >$75,000 (vs. <$25,000) 11.8 9.0 0.19 
Baseline BMI (centered at the median) -0.4 0.4 0.39 
Percent weight change from baseline 1.2 0.4 0.002 
Daily/weekly MVI with minerals use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
0.6 14.5 0.97 
Daily/weekly MVI with minerals use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
0.8 10.9 0.94 
Daily/weekly MVI with minerals use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
1.0 10.3 0.92 
Daily/weekly iron supplement use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
1.1 13.1 0.93 
Daily/weekly iron supplement use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
13.2 7.2 0.07 
Daily/weekly iron supplement use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
25.5 11.6 0.03 
Abbreviations: RYGB: Roux-en-Y gastric bypass; LAGB: laparoscopic adjustable gastric banding;  
BMI: body mass index; MVI: multivitamin 
 
  
Table 25 shows the parsimonious multivariable model.  Annual household income was 
added to the model based on the statistical significance of the multiple degree of freedom test 
(p=.04) in the simple linear model.     
 
 
 
108 
Table 25:  Multivariable linear regression for change in serum ferritin – Parsimonious 
Model (n=314) 
 
P-value for the model:  0.001 
Adjusted R-squared: 0.08 
Variable Parameter 
Estimate 
Standard 
Error 
p 
Intercept -35.7 12.9 0.01 
RYGB (vs. LAGB) -38.3 9.9 0.0001 
Black race (vs. white) -10.4 9.8 0.29 
Annual household income: $25,000-$49,999 (vs. <$25,000) 17.4 8.2 0.04 
Annual household income: $50,000-$74,999 (vs. <$25,000) -4.8 8.4 0.57 
Annual household income: >$75,000 (vs. <$25,000) 10.3 8.3 0.22 
Percent weight change from baseline 1.2 0.4 0.001 
Daily/weekly MVI with minerals use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
-1.1 14.2 0.94 
Daily/weekly MVI with minerals use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
0.03 10.6 1.0 
Daily/weekly MVI with minerals use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
0.3 10.2 0.98 
Daily/weekly iron supplement use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
0.1 12.9 1.0 
Daily/weekly iron supplement use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
13.1 7.2 0.07 
Daily/weekly iron supplement use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
24.8 11.4 0.03 
Abbreviations: RYGB: Roux-en-Y gastric bypass; LAGB: laparoscopic adjustable gastric banding; MVI: 
multivitamin 
 
When adding the other covariates to the parsimonious model stepwise, only baseline 
serum ferritin had a p<.05.  Household income was no longer significant and was removed from 
the model.  The overall clinical site effect was tested using the multiple degree of freedom test 
and was not significant (p=.29); therefore, clinical sites were removed from the final model.   
The final model is presented in Table 26.  The assumptions for multivariable linear regression 
were tested for the final model.  The residuals for the model were normally distributed.  There 
was no violation of homoscedasticity or linearity, and no collinearity was identified among the 
independent variables.   
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Table 26:  Final Model:  Association of bariatric surgery and change in serum ferritin level 
based on multivariable linear regression (n=325) 
 
P-value for the model:  <.0001 
Adjusted R-squared: 0.23 
Variable Parameter 
Estimate 
Standard 
Error 
p 
Intercept -1.2 12.0 0.92 
RYGB (vs. LAGB)*^ -59.3 17.3 0.001 
Black race (vs. white) -6.2 8.0 0.44 
Percent weight change from baseline* 0.6 0.5 0.25 
Daily/weekly MVI with minerals use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
8.3 12.4 0.51 
Daily/weekly MVI with minerals use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
0.7 9.4 0.94 
Daily/weekly MVI with minerals use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
7.2 9.0 0.42 
Daily/weekly iron supplement use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
-6.9 11.8 0.56 
Daily/weekly iron supplement use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
5.1 6.0 0.40 
Daily/weekly iron supplement use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
13.6 10.1 0.18 
Baseline serum ferritin^ -0.2 0.1 0.001 
*Interaction of type of surgery and percent weight change 
from baseline 
1.4 0.6 0.03 
^Interaction of type of surgery and baseline serum ferritin -0.2 0.1 0.02 
Abbreviations: RYGB: Roux-en-Y gastric bypass; LAGB: laparoscopic adjustable gastric banding; MVI: 
multivitamin 
 
 
The type of bariatric surgery was significantly (p=.001) associated with change in serum 
ferritin from baseline to one year following surgery, after adjusting for the covariates in the 
model, such that women who had undergone RYGB had a lower change in serum ferritin than 
women who had undergone LAGB.  There were significant interactions between type of surgery 
with both percent weight change from baseline (p=0.03) and baseline serum ferritin level 
(p=0.02), such that the difference in change in serum ferritin between RYGB and LAGB was less 
pronounced with greater weight loss and more pronounced with higher baseline ferritin level.  
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4.3.2.1 How surgical procedure moderates associations  
The association between percent weight change and change in serum ferritin is moderated by 
type of surgery.  To illustrate this interaction, the plot in Figure 17 was constructed for predicted 
change in serum ferritin based on the final regression model (Table 26) with independent 
variables fixed at the following values: white race, reported daily/weekly MVI with minerals use 
at baseline and follow-up, reported daily/weekly iron supplement use at follow-up, and baseline 
serum ferritin at the median level (57.5 ng/mL) for both surgical procedures.  The results in 
Figure 17 indicate that while for both surgical procedures, with greater percent weight change 
(i.e. more weight loss or less weight gain) there is a greater change in serum ferritin (i.e. greater 
decrease or smaller increase in serum ferritin from baseline to the one-year post-operative visit).  
In the case of RYGB, the predicted change in serum ferritin goes from a decrease to an increase 
above 30.2% weight change.  For LAGB, the predicted change in serum ferritin goes from a 
decrease to an increase above 0.05% weight change. The interaction shows that the increase in 
serum ferritin with more percent weight loss was more pronounced among women who had 
undergone RYGB compared to LAGB.    
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Abbreviations:  LAGB: laparoscopic adjustable gastric banding; RYGB:  Roux-en-Y gastric bypass; 
%ile: percentile; MVI: multivitamin 
Note: Change in serum ferritin was determined by subtracting the baseline serum level from the  
one-year postoperative serum level.  Percent weight change was calculated as weight at baseline minus 
weight at the one-year postoperative follow-up visit divided by weight at baseline, and multiplied by 100.  
A positive value for percent weight change indicates weight loss and a negative value indicates weight 
gain. 
 
Figure 17:  Interaction of Surgery and Percent Weight Change 
 
The association between baseline serum ferritin level and change in serum ferritin is also 
moderated by type of surgery.  Figure 18 shows a plot of predicted change in serum ferritin using 
the variables included in the final regression model fixed at the following values: white race, 
percent weight change from baseline at the median (31.4%), reported daily/weekly MVI with 
minerals use at baseline and follow-up, and reported daily/weekly iron supplement use at follow-
up for both surgical procedures.  Figure 18 shows that while participants with higher baseline 
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serum ferritin levels have smaller predicted increases or larger predicted decreases in serum 
ferritin, the predicted change in serum ferritin was more pronounced among the women who had 
undergone RYGB compared to LAGB. 
 
 
Abbreviations:  LAGB: laparoscopic adjustable gastric banding; RYGB:  Roux-en-Y gastric bypass; 
%ile: percentile; MVI: multivitamin 
Note: Change in serum ferritin was determined by subtracting the baseline serum level from the one-year 
postoperative serum level. 
 
Figure 18:  Interaction of Surgery and Baseline Serum Ferritin 
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4.3.3 Association of bariatric surgery and iron deficiency 
The subjects’ serum levels at baseline and one-year follow-up were classified as deficient (<15 
ng/mL), within the normal range (15-150 ng/mL), and above the normal range/high (>150 
ng/mL).  Table 27 shows deficiency status by surgery, separately for baseline and follow-up.  
Prior to surgery, 8.2% of subjects who underwent LAGB and 6.8% of subjects who underwent 
RYGB were iron-deficient, based on serum ferritin level.  The difference in prevalence of 
deficiency at baseline by surgery was not significant.  One year after surgery, there was a 
significantly (p=.04) smaller percentage of LAGB subjects who were iron deficient (13.7%) 
compared RYGB subjects (21.8%).  Of the four subjects who reported being pregnant at the one-
year postoperative follow-up visit, none were deficient at baseline and one subject was iron-
deficient at one-year follow-up.  
 
Table 27:  Ferritin deficiency status by surgery at baseline and one-year follow-up 
 LAGB 
(n=146) 
RYGB 
(n=280) 
P 
 n (%) n (%)  
At baseline:    
    Deficient 12 (8.2) 19 (6.8) 0.59 
    Not-deficient  134 (91.8) 261 (93.2)  
    
At 1-year follow-up:    
    Deficient 20 (13.7) 61 (21.8) 0.04 
    Not-deficient 126 (86.3) 219 (78.2)  
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB:  
Roux-en-Y gastric bypass; n: number of subjects 
 
 
Ferritin status (deficient, within the normal range, or high) at both time points are 
presented in Table 28 (LAGB group) and Table 29 (RYGB group).  In the LAGB group, 9.2% of 
114 
subjects whose serum ferritin was in the normal range at baseline were deficient one year after 
surgery.  Overall, the distributions at baseline and follow-up did not change significantly (p=.10).  
For subjects who underwent RYGB, 20.8% of subjects who were within the normal range prior 
to surgery were iron-deficient one year following surgery and the overall distributions changed 
pre- to post-surgery such that a greater percentage of subjects went from the normal range to 
deficient or high to the normal range rather than changing from deficient to the normal range or 
the normal range to high (p<.0001). 
 
Table 28:  Ferritin sufficiency status at baseline and one-year postoperative for the LAGB 
group  
 
 Ferritin Status at 1-Year Follow-up (LAGB) 
Ferritin Status at 
Baseline (LAGB) 
 
 
Deficient 
 
 
Normal 
Range 
 
 
High 
Total 
(frequency, 
percent) 
Deficient 
(frequency, row 
percentage) 
9 
75.0% 
3 
25.0% 
0 
    0% 
12 
8.2% 
Normal range 
(frequency, row 
percentage) 
11 
9.2% 
102 
8.0% 
7 
5.8% 
120 
82.2% 
High 
(frequency, row 
percentage) 
0 
0% 
3 
21.4% 
11 
78.6% 
14 
9.6% 
Total (frequency, 
percentage) 
20 
13.7% 
108 
74.0% 
18 
12.3% 
146 
100.0% 
Abbreviations: LAGB: laparoscopic adjustable gastric banding 
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Table 29:  Ferritin sufficiency status at baseline and one-year postoperative for the RYGB 
group 
 
 Ferritin Status at 1-Year Follow-up (RYGB) 
Ferritin Status at 
Baseline (RYGB) 
 
 
Deficient 
 
 
Normal 
Range 
 
 
High 
Total 
(frequency, 
percent) 
Deficient 
(frequency, row 
percentage) 
13 
68.4% 
6 
31.6% 
0 
0% 
19 
6.8% 
Normal range 
(frequency, row 
percentage) 
48 
20.8% 
174 
75.3% 
9 
3.9% 
231 
82.5% 
High 
(frequency, row 
percentage) 
0 
0% 
14 
46.7% 
16 
53.3% 
30 
10.7% 
Total (frequency, 
percentage) 
61 
21.8% 
194 
69.3% 
25 
8.9% 
280 
100.0% 
Abbreviations: RYGB: Roux-en-Y gastric bypass 
 
 
Plots of individual continuous covariates versus ferritin deficiency status (not deficient or 
deficient) are presented in Figure 19.  Contingency tables for categorical variables are presented 
in Tables 30 – 38. 
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Abbreviations: BMI: body mass index 
Figure 19:  Box plots of continuous variables and ferritin deficiency status 
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Figure 19 (continued):  Box plots of continuous variables and ferritin deficiency status 
 
 
Table 30:  Ferritin deficiency status at one-year follow-up by type of surgery 
 Deficient 
(n=81) 
Not Deficient 
(n=345) 
p 
Surgery n (%) n (%) 0.04 
LAGB (n=146) 20 (13.7) 126 (86.3)   
RYGB (n=280) 61 (21.8) 219 (78.2)  
Abbreviations: LAGB: laparoscopic adjustable gastric banding; RYGB: Roux-en-Y gastric bypass 
 
 
 
Table 31:  Ferritin deficiency status at one-year follow-up by race 
 Deficient  
(n=81) 
Not Deficient 
(n=341) 
p 
Race n (%) n (%) 0.03 
White (n=365) 63 (17.3) 302 (82.7)  
Black (n=44) 15 (34.1) 29 (65.9)  
Other or Multiple 
Races (n=13) 
3 (23.1) 10 (76.9)  
Missing (n=4) 0 4 
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Table 32:  Ferritin deficiency status at one-year follow-up by ethnicity 
 Deficient 
(n=81) 
Not Deficient 
(n=345) 
p 
Ethnicity n (%) n (%) 0.21 
Non-Hispanic (n=393) 72 (18.3) 321 (81.7) 
 
 
Hispanic (n=33)  9 (27.3) 24 (72.7)  
 
 
Table 33:  Ferritin deficiency status at one-year follow-up by annual household income 
 Deficient 
(n=73) 
Not Deficient 
(n=322) 
p 
Annual Income n (%) n (%) 0.36 
<$25,000 (n=75)  16 (21.3) 59 (78.7)  
$25,000-$49,999 (n=109) 23 (21.1) 86 (78.9)  
$50,000-$74,999 (n=100) 14 (14.0) 86 (86.0)  
>$75,000 (n=111) 20 (18.0) 91 (82.0)  
Missing (n=31) 8 23  
 
 
 
Table 34: Ferritin deficiency status at one-year follow-up by highest level of education 
completed 
 
 Deficient 
(n=77) 
Not Deficient 
(n=327) 
p 
Education n (%) n (%) 0.24 
< High School (n=84) 21 (25.0) 63 (75.0)  
Some College (n=163)  28 (17.2) 135 (82.8)  
> College Degree (n=157) 28 (17.8) 129 (82.2)  
Missing (n=22) 4 18  
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Table 35: Ferritin deficiency status at one-year follow-up by MVI with minerals 
supplement use at one-year follow-up 
 
 Deficient 
(n=67) 
Not Deficient 
(n=301) 
p 
MVI with Minerals Use at 
1-Year Follow-up 
n (%) n (%) 0.02 
None/Rarely/Monthly (n=56) 15 (26.8) 41 (73.2)  
Weekly (n=49)  12 (24.5) 37 (75.5)  
Daily (n=263) 40 (15.2) 223 (84.8)  
Missing (n=58) 14 44  
Abbreviations: MVI: multivitamin 
 
 
Table 36:  Ferritin deficiency status at one-year follow-up by iron supplement use at one-
year follow-up 
 
 Deficient 
(n=71) 
Not Deficient 
(n=313) 
p 
Iron Supplement Use at 1-
Year Follow-up 
n (%) n (%) 0.30 
None/Rarely/Monthly (n=250) 50 (20.0) 200 (80.0)  
Daily or Weekly (n=134)  21 (15.7) 113 (84.3)  
Missing (n=42) 10 32  
 
 
 
Table 37:  Ferritin deficiency status at one-year follow-up by use of histamine H2 receptor 
antagonist medication at one-year follow-up 
 
 Deficient 
(n=71) 
Not Deficient 
(n=315) 
p 
Histamine H2 Receptor 
Antagonist Use 
n (%) n (%) 0.30 
No (n=359) 64 (17.8) 295 (82.2)  
Yes (n=27)  7 (25.9) 20 (74.1)  
Missing (n=40) 10 30  
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Table 38:  Ferritin deficiency status at one-year follow-up by ferritin deficiency status at 
baseline 
 
 Deficient 
(n=81) 
Not Deficient 
(n=345) 
p 
Ferritin Deficiency Status at 
Baseline 
n (%) n (%) <.0001 
Deficient (n=31) 22 (71.0) 9 (29.0)  
Not Deficient (n=395)  59 (14.9) 336 (85.1)  
  
 
Parameter estimates, p-values, adjusted odds ratios with 95% confidence intervals, and 
model statistics for the base multivariable logistic regression model for association of bariatric 
surgery and ferritin deficiency are presented in Table 39.  LABS clinical site was not included in 
the logistic regression models because of lack of convergence due to one of the clinical sites 
having no cases of ferritin deficiency. 
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Table 39: Multivariable logistic regression for ferritin deficiency – Base Model (n=333)  
P-value for the model:  0.18 
AIC: 326.40 
c-statistic:  0.69 
Variable Parameter 
Estimate 
Standard 
Error 
p Adjusted 
OR 
95% CI 
Intercept -1.3 0.6 0.04   
RYGB (vs. LAGB) 1.5 0.5 0.01 4.56 (1.59-13.12) 
Age at surgery (centered at the median) -0.01 0.03 0.76 0.99 (0.95-1.04) 
Black race (vs. white) 0.7 0.4 0.12 1.94 (0.84-4.52) 
Other race or multiple races (vs. white) 0.3 0.7 0.65 1.40 (0.33-5.87) 
Hispanic ethnicity (vs. non-Hispanic) 0.3 0.6 0.69 1.29 (0.38-4.37) 
Some college education (vs. high school 
diploma or less) 
-0.2 0.4 0.58 0.80 (0.36-1.77) 
College degree or higher (vs. high school 
diploma or less) 
0.02 0.4 0.97 1.02 (0.44-2.35) 
Annual household income: $25,000-
$49,999 (vs. <$25,000) 
0.1 0.4 0.83 1.09 (0.48-2.50) 
Annual household income: $50,000-
$74,999 (vs. <$25,000) 
-0.6 0.5 0.21 0.54 (0.20-1.43) 
Annual household income: >$75,000 (vs. 
<$25,000) 
-0.1 0.5 0.77 0.87 (0.34-2.21) 
Baseline BMI (centered at the median) -0.001 0.02 0.97 1.00 (0.96-1.04) 
Percent weight change from baseline -0.03 0.02 0.18 0.98 (0.94-1.01) 
Weekly MVI with minerals use at the 1-
year postoperative follow-up visit (vs. 
none/rarely/monthly use) 
0.1 0.5 0.79 1.15 (0.40-3.29) 
Daily MVI with minerals use at the 1-
year postoperative follow-up visit (vs. 
none/rarely/monthly use) 
-0.5 0.4 0.25 0.62 (0.27-1.40) 
Daily/weekly iron supplement use at the 
1-year postoperative follow-up visit (vs. 
none/rarely/monthly use) 
-0.5 0.3 0.14 0.61 (0.32-1.18) 
Abbreviations: AIC: Akaike information criterion; OR: odds ratio; CI: confidence interval; RYGB: Roux-
en-Y gastric bypass; LAGB: laparoscopic adjustable gastric banding; BMI: body mass index; MVI: 
multivitamin 
 
 
 
The only variable that was significant in the base model was surgery.  Table 40 shows the 
parsimonious multivariable model.    Ferritin deficiency status at baseline was added to the 
model based its statistical significance in the simple regression model (p<.0001).   When adding 
the other covariates stepwise to the parsimonious model, none of the variables were statistically 
significant.  Therefore, the parsimonious model is the final model presented in Table 40.  No 
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significant interactions were identified in the final main effects model.  Model diagnostics and 
the assumptions for multivariable logistic regression were tested for the final model.  Based on 
the Hosmer-Lemeshow test, there was no evidence of lack of fit.  There was no evidence of 
multicollinearity.   
 
Table 40:  Final Model:  Association of bariatric surgery and ferritin deficiency based on 
multivariable logistic regression (n=359) 
 
P-value for the model:  <.0001 
AIC: 311.28 
c-statistic:  0.73 
Variable Parameter 
Estimate 
Standard 
Error 
p Adjusted 
OR 
95% CI 
Intercept -2.0 0.4 <.0001   
RYGB (vs. LAGB) 1.4 0.4 0.0004 3.99 (1.85-8.59) 
Black race (vs. white) 0.4 0.5 0.38 1.49 (0.61-3.64) 
Weekly MVI with minerals use at the 1-
year postoperative follow-up visit (vs. 
none/rarely/monthly use) 
-0.04 0.5 0.94 0.96 (0.37-2.52) 
Daily MVI with minerals use at the 1-
year postoperative follow-up visit (vs. 
none/rarely/monthly use) 
-0.9 0.4 0.02 0.40 (0.18-0.86) 
Daily/weekly iron supplement use at the 
1-year postoperative follow-up visit (vs. 
none/rarely/monthly use) 
-0.5 0.3 0.12 0.59 (0.31-1.14) 
Ferritin deficient at baseline (vs. not 
deficient) 
2.7 0.5 <.0001 14.37 4.96-41.59 
Abbreviations: AIC: Akaike information criterion; OR: odds ratio; CI: confidence interval; RYGB: Roux-
en-Y gastric bypass; LAGB: laparoscopic adjustable gastric banding; MVI: multivitamin 
 
 
Those who had undergone RYGB had greater odds of ferritin deficiency one year after 
bariatric surgery compared to those who had undergone LAGB, with an adjusted odds ratio 
(AOR) of 3.99 (95% CI: 1.85-8.59) after adjusting for the other covariates in the model (Black 
race, weekly MVI with minerals use at follow-up, daily MVI with minerals use at follow-up, 
daily/weekly iron supplement use at follow-up, and ferritin deficiency status at baseline).   
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4.3.4 Factors associated with change in serum ferritin level from baseline to one year 
after RYGB 
Plots of individual covariates versus change in serum ferritin for subjects who had undergone 
RYGB (n=280) are presented in Figure 20 and Figure 21.    
 
 
Figure 20:  Scatter plots of continuous variables and change in serum ferritin after RYGB 
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Abbreviations:  BMI: body mass index 
 
 
Figure 20 (continued):  Scatter plots of continuous variables and change in serum ferritin 
after RYGB 
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Figure 21:  Box plots of categorical variables and change in serum ferritin after RYGB 
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Figure 21 (continued):  Box plots of categorical variables and change in serum ferritin after 
RYGB 
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Abbreviations:  MVI: multivitamin 
 
 
Figure 21 (continued):  Box plots of categorical variables and change in serum ferritin after 
RYGB 
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Figure 21 (continued):  Box plots of categorical variables and change in serum ferritin after 
RYGB 
 
 
 
Parameter estimates, p-values, and model statistics from the base multivariable model for 
factors associated with change in serum ferritin among women who had undergone RYGB are 
presented in Table 41.  The reduction in the sample size for the model (compared to total n=280) 
is due to missing data for individual variables. 
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Table 41:  Multivariable linear regression for change in serum ferritin after RYGB – Base 
Model (n=211) 
 
P-value for the model:  0.001 
Adjusted R-squared: 0.13 
Variable Parameter 
Estimate 
Standard 
Error 
p 
Intercept -112.3 24.9 <.0001 
Age at surgery (centered at the median) 0.4 0.6 0.47 
Black race (vs. white) -2.1 11.8 0.86 
Other race or multiple races (vs. white) -0.2 19.5 0.99 
Hispanic ethnicity (vs. non-Hispanic) 2.9 16.3 0.86 
Some college education (vs. high school diploma or less) -5.7 9.4 0.54 
College degree or higher (vs. high school diploma or less) -7.9 10.4 0.45 
Annual household income: $25,000-$49,999 (vs. <$25,000) 22.2 10.1 0.03 
Annual household income: $50,000-$74,999 (vs. <$25,000) 1.0 11.2 0.93 
Annual household income: >$75,000 (vs. <$25,000) 19.8 11.8 0.10 
Baseline BMI (centered at the median) -0.5 0.5 0.36 
Percent weight change from baseline 2.1 0.5 <.0001 
Daily/weekly MVI with minerals use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
20.8 21.9 0.34 
Daily/weekly MVI with minerals use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
5.1 15.7 0.74 
Daily/weekly MVI with minerals use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
5.4 15.5 0.73 
Daily/weekly iron supplement use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
-18.3 17.4 0.29 
Daily/weekly iron supplement use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
6.9 8.7 0.43 
Daily/weekly iron supplement use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
18.0 13.4 0.18 
Abbreviations: BMI: body mass index; MVI: multivitamin 
 
 
 
Percent weight change from baseline was significant in the base model.  Table 42 shows 
the parsimonious multivariable model.  Annual household income was not included in the 
parsimonious model based on the results of the multiple degree of freedom test for education 
(p=.13). 
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Table 42:  Multivariable linear regression for change in serum ferritin after RYGB – 
Parsimonious Model (n=218) 
 
P-value for the model:  <.0001 
Adjusted R-squared: 0.14 
Variable Parameter 
Estimate 
Standard 
Error 
p 
Intercept -109.8 22.2 <.0001 
Black race (vs. white) -5.7 11.5 0.62 
Percent weight change from baseline 2.3 0.5 <.0001 
Daily/weekly MVI with minerals use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
18.2 21.2 0.39 
Daily/weekly MVI with minerals use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
4.3 15.0 0.78 
Daily/weekly MVI with minerals use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
4.2 14.8 0.78 
Daily/weekly iron supplement use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
-18.7 17.2 0.28 
Daily/weekly iron supplement use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
8.8 8.6 0.31 
Daily/weekly iron supplement use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
14.9 12.9 0.25 
Abbreviations: MVI: multivitamin 
 
 
 
When adding the other covariates to the parsimonious model stepwise, only baseline 
serum ferritin had a p<.05.  Table 43 presents the final model.  The variable percent weight 
change was modified to 5% weight change for more meaningful interpretation.  No significant 
interactions were identified in the final main effects model.  The assumptions for multivariable 
linear regression were tested with no violations identified.  The residuals for the model were 
normally distributed.  There was no evidence of heteroscedasticity, non-linearity between the 
dependent and independent variables, or collinearity among the independent variables in the final 
model.   
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Table 43:  Final Model: Factors associated with change in serum ferritin level from 
baseline to one year following RYGB among women of childbearing age (n=218) 
 
P-value for the model:  <.0001 
Adjusted R-squared: 0.29 
Variable Parameter 
Estimate 
Standard 
Error 
p 
Intercept -80.3 20.6 0.0001 
Black race (vs. white) -2.2 10.4 0.83 
5% weight change from baseline 11.5 2.1 <.0001 
Daily/weekly MVI with minerals use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
17.2 19.2 0.37 
Daily/weekly MVI with minerals use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
1.8 13.6 0.89 
Daily/weekly MVI with minerals use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
7.1 13.4 0.60 
Daily/weekly iron supplement use at baseline only (vs. no 
daily/weekly use at baseline or follow-up) 
-17.4 15.6 0.27 
Daily/weekly iron supplement use at follow-up only (vs. no 
daily/weekly use at baseline or follow-up) 
1.9 7.9 0.81 
Daily/weekly iron supplement use at baseline and follow-up 
(vs. no daily/weekly use at baseline or follow-up) 
7.7 11.7 0.52 
Baseline serum ferritin -0.4 0.1 <.0001 
Abbreviations: MVI: multivitamin 
 
 
Percent weight change from baseline was significantly (p<.0001) associated with change 
in serum ferritin among women who underwent RYGB.  For every 5% weight change from 
baseline, the change in serum ferritin increases by 11.5 ng/mL, after adjusting for the other 
covariates in the model (Black race, daily/weekly MVI with minerals use, daily/weekly iron 
supplement use, and baseline serum ferritin), and the fixed effects of LABS clinical site.  The 
overall clinical site effect was significant (p=.01) so clinical sites were retained in the final 
model.  This model confirms that the association between percent weight change and serum 
ferritin differs by type of surgery.  Baseline serum ferritin level was also significantly (p<.0001) 
associated with change in serum ferritin, after adjusting for the other covariates in the model and 
the fixed effects of LABS clinical site. 
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5.0  DISCUSSION 
The primary purpose of this research was to determine the association between two types of 
bariatric surgery, RYGB and LAGB, and the change in serum folate and change in serum ferritin 
from prior to surgery to one year following surgery among women of childbearing age (18-45 
years).  The hypothesis for this aim was that women who underwent RYGB would have a larger 
decrease in serum folate and serum ferritin compared to women who underwent LAGB due to 
issues related to malabsorption of micronutrients.  This research also aimed to determine the 
prevalence of folate and iron deficiency prior to and one year after RYGB and LAGB and to 
identify factors associated with change in serum folate and change in serum ferritin levels 
specifically among women of childbearing age who had undergone RYGB.   
The population of interest for the study was women of childbearing age due to the 
important role of folate and iron during pregnancy for proper fetal development.  It is 
recommended that women avoid becoming pregnant for 12-18 months following bariatric 
surgery due to the increased risk of micronutrient deficiencies associated with bariatric surgery.11   
The study had 413 subjects (272 RYGB, 141 LABG) for the folate analyses and 426 subjects (280 
RYGB, 146 LAGB) for the serum ferritin analyses.  The subjects were a subset of the female 
participants from the LABS-2 study.   
To investigate the aims of the study, serum samples stored at the NIDDK Central 
Repository were used to determine preoperative and one-year postoperative serum folate and 
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serum ferritin levels for each subject.  Serum ferritin was used as an indicator of iron status.  The 
time point of one year following surgery was selected because it falls at the beginning of the time 
period when it is considered safe for women to become pregnant after bariatric surgery.  The 
serum analyses were conducted by the staff at the Heinz Nutrition Laboratory.  The change in 
serum folate and change in serum ferritin from baseline to one year following bariatric surgery as 
well as deficiency status for each micronutrient were determined and statistical analyses were 
conducted to address the second and third aims of the study.   
5.1 CHANGE IN SERUM FOLATE AND FOLATE DEFICIENCY AFTER RYGB 
AND LAGB 
5.1.1 Change in serum folate from baseline to one year following bariatric surgery among 
women of childbearing age  
The results of the folate analyses presented a number of unexpected findings including median 
values for serum folate at one year after surgery within the normal range for the women who 
underwent LAGB (22.3 ng/mL) and above the normal range for the women underwent RYGB 
(26.0 ng/mL).  Blume et al.89, Donadelli et al.91, Coupaye et al.94, and Coupaye et al.95 reported 
increases in the median or mean serum folate levels from pre-op to one year after RYGB; 
however, the median or mean serum levels at one year post-op were not as high as in this study 
(range of 13.3–17.6 ng/mL).  The mean change in serum folate after LAGB was a decrease of 
4.3 ng/mL from baseline to one year after surgery, and the mean change after RYGB was an 
increase of 2.8 ng/mL. 
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Based on multivariable linear regression, there was a not a significant difference in the 
change in serum folate from baseline to one year after surgery by type of surgery, after adjusting 
for other covariates in the model.  These results are in contrast to the hypothesis for the study 
that women who underwent RYGB would have a greater decrease in serum folate from baseline 
to one year after surgery than women who underwent LAGB.   
When focusing on the women who underwent RYGB (n=272) to address the third aim of 
the study, daily/weekly MVI use at follow-up only and daily/weekly MVI use at both baseline 
and follow-up were negative confounders of the relationship between RYGB and change in 
serum folate.  Daily/weekly MVI use at follow-up only was associated, on average, with a 10.9 
ng/mL greater change in serum folate (p=.04), and daily/weekly MVI use at both baseline and 
follow-up was associated, on average, with a 12.3 ng/mL greater change in serum folate (p=.02) 
compared to no daily/weekly use at either time point, after adjusting for the other covariates in 
the model.  Surprisingly, daily/weekly use of a folate supplement at both baseline and follow-up, 
on average, resulted in a 17.5 ng/mL lower change in serum folate level (p=.04) compared to no 
daily/weekly use of a folate supplement at baseline or follow-up, after adjusting for the other 
covariates in the model.  As would be expected, baseline serum folate was significantly 
(p<.0001) associated with change in serum folate, after adjusting for the other covariates. 
5.1.2 Bariatric surgery and the prevalence of folate deficiency 
The prevalence of folate deficiency for all subjects (n=413) was low before surgery (0.2%) and 
one year after surgery (1.0%) and did not differ significantly by type of surgery (0.7% after 
LAGB vs. 1.1% after RYGB; p=1.00).  The prevalence of folate deficiency one year after 
surgery was similar to the overall prevalence of 0.9% among women of childbearing age in the 
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U.S.61  At one year after LAGB, the prevalence of folate deficiency found in this study was 
lower than the 10.0% prevalence of deficiency (based on serum folate equivalent to <3 ng/mL) 
reported by Coupaye et al.94 in a small study of 21 subjects (18 women, 3 men).  The prevalence 
of deficiency one year after RYGB was similar to what was reported by Blume et al.89, Donadelli 
et al.91, Coupaye et al.94, and Coupaye et al.95 but lower than what was reported by Dogan et al.90  
and Toh et al.93 one year after surgery.  Blume et al.89 reported 1.2% prevalence of deficiency 
based on serum folate <2.8 ng/mL in a study of 170 subjects (136 women, 34 men).  In a study 
of 58 subjects (46 women, 12 men), Donadelli et al.91 reported 3.4% prevalence of deficiency 
based on serum folate <3 ng/mL.  Coupaye et al.94 reported no cases of folate deficiency one 
year after RYGB using diagnostic criteria of serum folate equivalent to <3 ng/mL in a cohort of 
49 subjects (45 women, 4 men).  In their 2014 study, Coupaye et al.95 reported 3.0% prevalence 
of folate deficiency among 43 subjects (31 women, 12 men) using the same diagnostic criteria as 
in their prior study.  In contrast, Dogan et al.90 reported 6.8% prevalence of deficiency in a 
cohort of 74 subjects (51 women, 23 men) based on serum folate equivalent to <3.97 ng/mL.  
Toh et al.93 reported 12.0% prevalence of folate deficiency in a study of 103 subjects (number of 
women vs. men not specified); however, RBC folate was used to identify deficiency rather than 
serum folate.   Similar to this study, the majority of researchers used serum folate to define folate 
deficiency with a range of <2.8-4.0 ng/mL.    
 One year after surgery, the majority of the women in this study who had undergone 
LAGB had serum folate levels within the normal range (55.3%) or above the normal range 
(44.0%).  For those who underwent RYGB, 46.0% had serum folate levels within the normal 
range and 52.9% had levels above the normal range one year following surgery.   
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The use of MVI supplements (which typically contain folate) may have played a role in 
these findings since the percentage of women who reported daily MVI supplement use at the 
one-year postoperative visit was 58.0% for women who underwent LAGB and 83.8% for those 
who underwent RYGB.  The American Society for Metabolic and Bariatric Surgery recommends 
that women of childbearing age take 800-1000 µg per day of supplemental folate from their 
multivitamin.23,28  MVI supplements commonly provide 400 µg in one dose49, but amounts 
provided in supplements can vary widely.  Due to the potential to mask vitamin B12 deficiency, 
supplementation of folate above 1000 µg per day is not recommended.23  The serum folate test 
used in this study is an indicator of short-term folate status and recent intake rather than long-
term folate status.51,55  Therefore, the serum levels may have been elevated due to recent 
supplement use.   
Another possible cause of the high serum folate levels is vitamin B12  deficiency55, a 
commonly reported deficiency related to bariatric surgery10.  However, determination of vitamin 
B12 status was beyond the scope of this study.    
 Based on the results of this study, folate deficiency at one year after LAGB and RYGB 
was rare.  However, these results should be interpreted with caution based on the diagnostic test 
used to identify folate deficiency, as discussed in the Study Limitations section.   
A potential concern, based on the results of the study, is the large proportion of subjects 
with serum folate levels above the normal range.  It may be possible that individuals were 
receiving too much folic acid after bariatric surgery from a combination of supplements 
containing folic acid and consumption of grains and cereals fortified with folic acid.  
Consequences of excessive folate supplementation and resulting high serum folate levels must be 
considered.  A recent study by Raghavan et al.110 of 1257 mother-child pairs from Boston 
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Medical Center reported that mothers with plasma folate levels of > 60.3 nmol/L at birth 
(equivalent to > 26.6 ng/mL) had a higher risk of having a child with Autism Spectrum Disorder 
[adjusted hazard ratio (HR) of 2.5; 95% CI: 1.3-4.6].  Mothers who reported taking a MVI 
supplement more than five times a week during pregnancy also had a higher risk of having a 
child with Autism Spectrum Disorder [adjusted HR of 2.3 (95% CI: 1.2-3.9) for MVI use in the 
first trimester; adjusted HR of 2.1 (95% CI: 1.2-3.6) for MVI use in the second and third 
trimesters].   
5.2 CHANGE IN SERUM FERRITIN AND IRON DEFICIENCY AFTER RYGB AND 
LAGB 
5.2.1 Change in serum ferritin from baseline to one year following bariatric surgery 
among women of childbearing age  
The unadjusted mean change in serum ferritin was a decrease of 3.8 ng/mL after LAGB and a 
decrease of 11.9 ng/mL after RYGB.  In the multivariable linear regression model, there were 
significant interactions between type of surgery with both percent weight change from baseline 
and baseline serum ferritin level, such that the difference in change in serum ferritin between 
RYGB and LAGB was larger with less weight loss and higher baseline ferritin level.     
These interactions also showed that the associations of percent weight change and baseline 
ferritin, respectively, with change in serum ferritin were more pronounced among women who 
had undergone RYGB compared to LAGB.   
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The third aim of the study was to determine factors associated with change in serum 
ferritin specifically among women of childbearing age who underwent RYGB (n=280).  Percent 
weight change from baseline was significantly (p<.0001) associated with change in serum 
ferritin from baseline to one year after RYGB.  For every 5% weight change from baseline, 
serum ferritin increased by 11.5 ng/mL, after adjusting for the other covariates in the model and 
the fixed effects of clinical site.  Baseline serum ferritin was significantly (p<.0001) associated 
with change in serum ferritin, after adjusting for the other covariates and fixed effects of clinical 
site. 
The direction of the relationship between percent weight change and change in serum 
ferritin was in contrast with the hypothesis that a greater weight loss would be associated with a 
greater decrease in serum ferritin since the mechanisms that produce weight loss after bariatric 
surgery (i.e. decreased oral intake and malabsorption) could also increase the risk of nutrient 
deficiencies.23  However, it has been suggested that weight loss could play a role in increasing 
serum ferritin levels.111  Ferritin can be stored in activated hepatic adipocytes.112  A possible 
mechanism of action for higher serum ferritin levels with greater weight loss could be increased 
release of ferritin due to hepatic lipolysis to meet energy needs.  Also, the inflammation 
associated with obesity impairs intestinal absorption of iron, and so, weight loss may improve 
intestinal iron absorption.113  
MVI with minerals supplement use (which often contain iron) and iron supplement use 
were not found to have a significant association with change in serum ferritin after RYGB.  It is 
possible that there may have been a lack of power to detect an association due to missing data for 
these variables.  Twenty percent of the data for the daily/weekly MVI with minerals supplement 
use variable and 12.1% of the data for the daily/weekly iron supplement use variable were 
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missing for the subjects who underwent RYGB.   The parameter estimates for these variables 
were in the expected direction of greater change in serum ferritin with supplement use and had 
wide 95% confidence intervals, which indicate that lack of power may have been an issue.  Black 
race was also not significantly associated with change in serum ferritin.  Due to the low 
prevalence of African Americans in the study (10.4% of the total subjects), there may have been 
inadequate power to detect a significant association. 
5.2.2 Bariatric surgery and the prevalence of iron deficiency 
Prior to surgery, 7.3% of the women in the study had iron deficiency, as determined by serum 
ferritin level, as compared to the overall prevalence for women aged 20-49 years in the U.S. of 
13.2%.79  One year following surgery, the prevalence of iron deficiency for the total sample 
(n=426) increased significantly (p<.0001) to 19.0%.   The prevalence of iron deficiency was 
significantly (p=0.04) greater among women who had undergone RYGB than LAGB (21.8% vs. 
13.7%, respectively).  In the unadjusted analysis, the prevalence of iron deficiency was 34.1% 
for African American women vs. 17.3% for Caucasian women.  Based on multivariable logistic 
regression, women who had undergone RYGB had significantly greater odds of iron deficiency 
one year after surgery compared to women who had undergone LAGB (AOR 3.99; 95% CI: 
1.85-8.59), after adjusting for the covariates in the model.   
 The prevalence of iron deficiency one year after LABG was higher than reported by 
Coupaye et al.94 (5.0%) in a study of 21 subjects (18 women, 3 men).  However, Coupaye et al.94 
used a stricter diagnostic criterion for iron deficiency of serum ferritin equivalent to <3 ng/mL 
which would lead to fewer subjects being classified as iron-deficient. 
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 For RYGB, the prevalence of iron deficiency was higher than what was reported in the 
studies by Bavaresco et al.87, Blume et al.89, Dogan et al.90, Ikramuddin et al.92, Toh et al.93, and 
Coupaye et al.94 at one year after surgery.  Bavaresco et al.87 reported 14.6% prevalence of iron 
deficiency in a cohort of 48 subjects (41 women, 7 men) but used serum iron, rather than serum 
ferritin, as the diagnostic test.  In a study of 170 subjects (136 women, 34 men), Blume et al.89 
reported 4.1% prevalence of deficiency based on serum ferritin <10 ng/mL.  Dogan et al.90 
reported 10.7% prevalence of iron deficiency in a cohort of 74 subjects (51 women, 23 men) 
based on diagnostic criteria of serum ferritin equivalent to < 20 ng/mL.   Ikramuddin et al.92 
reported 14.0% prevalence of iron deficiency among 60 subjects (38 women, 22 men); however, 
diagnostic criteria for defining deficiency was not reported.  In a study of 103 subjects (number 
of women vs. men not specified), Toh et al.93 reported 15.0% prevalence of iron deficiency using 
the same diagnostic criteria as this study.  In the 2009 study by Coupaye et al.94, the prevalence 
of deficiency was 4.0% among a cohort of 49 subjects (45 women, 4 men) using a much stricter 
diagnostic criterion of serum ferritin equivalent <3 ng/ml.  The prevalence of iron deficiency one 
year after RYGB was similar to the 20% prevalence reported in the 2014 study by Coupaye et 
al.95 of 43 subjects (31 women, 12 men); however, the researchers used transferrin saturation 
rather than serum ferritin to identify deficiencies.   Differences in criteria used to identify iron 
deficiency may account for some of the differences in reported prevalence.    
 The results of this study indicate that iron deficiency is a concern for women at one year 
after LAGB and RYGB, but particularly for women after RYGB.  The prevalence of iron 
deficiency one year after LAGB is similar to the overall prevalence for women aged 20-49 years 
in the U.S., but the prevalence after RYGB is higher.  Based on the results of this study, it is  
recommended that all women be tested for iron deficiency at one year after RYGB using a 
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diagnostic test that is an indicator of early-stage iron deficiency such as serum ferritin and then 
treated if deficient to avoid the risks associated with iron deficiency in the periconceptional 
period and during pregnancy (e.g. maternal iron deficiency anemia during pregnancy, low infant 
iron stores at birth70, greater risk of preterm birth71-73, greater risk of infant low birth weight71, 
and interference with fetal neurodevelopment leading to difficulties with learning, language 
skills, emotional development, and motor skills74,75) and the consequences of iron deficiency for 
all adults (e.g. iron deficiency anemia, epithelial tissue disorders, decreased muscle function and 
exercise tolerance, and fatigue69). 
5.2.3 Pregnancy status 
Pregnancy was not an exclusion criterion for the study.  Therefore, pregnant and possibly 
pregnant women were included in all analyses.  There were four women (0.9% of subjects) who 
reported being pregnant and nine women (2.1% of subjects) who reported possibly being 
pregnant at the one-year postoperative follow-up visit.  The multivariable regression analyses for 
change in serum folate, change in serum ferritin, and ferritin deficiency status were conducted 
with and without the four women who reported being pregnant, with no significant differences in 
the results.  Therefore, the data for the pregnant women were included in the results of all 
statistical analyses.   
For the women who reported being pregnant, none were deficient in folate at baseline or 
at the one-year postoperative follow-up visit.  For iron deficiency, based on serum ferritin, none 
were deficient at baseline and one woman was deficient at the one-year postoperative follow-up 
visit.  For supplement use, two of the women reported taking a MVI with minerals daily at the 
one-year postoperative follow-up visit (data was missing for the other two women).  For folate 
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and iron supplement use, data was missing for one subject.  Of the other three women, none were 
taking a folate supplement, and one women reported taking an iron supplement on a daily basis 
at follow-up. 
5.3 STUDY LIMITATIONS 
The study had some limitations that should be noted.  LAGB is no longer as commonly 
performed as it was during the years when the LABS participants were undergoing surgery, and 
it has largely been replaced by the sleeve gastrectomy.1  The results from this study related to 
LAGB may not be as relevant at the current time.   
Self-report data were used for many of the covariates (i.e. supplement use, alcohol use) 
that were investigated for association with the outcomes of the study.  Results dependent on self-
report data can be subject to social desirability and recall bias.  Also, after bariatric surgery, as 
individuals may be able to decrease the dose or discontinue some of their medications due to 
improvements in obesity-related comorbidities114, there may be some hesitancy to take other 
medications or supplements.   
In addition, there were missing data for a number of the self-report variables.  In 
particular, MVI with minerals supplement use at follow-up (13.6% missing), number of 
alcoholic drinks consumed per day at follow-up (12.7%), alcohol use disorder symptoms at 
follow-up (12.2%), frequency of alcohol consumption at follow-up (12.0%), MVI with minerals 
use at baseline (10.6%), and iron supplement use at follow-up (9.9%).  Missing data were more 
prevalent at the one-year postoperative follow-up visit than at baseline.  
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While frequency of use data were available for the micronutrient supplements (MVI, 
MVI with minerals, folate, and iron), dosage was not available.  Brand names for the MVI and 
MVI with mineral supplements, which could have been used to determine dosage, were also not 
available.    The American Society for Metabolic and Bariatric Surgery recommends that 
individuals take a MVI with minerals supplement that provides 100% of the daily value for at 
least two-thirds of the nutrients after LAGB and a MVI with minerals supplement that provides 
200% of the daily value for at least two-thirds of the nutrients after RYGB (e.g. taking two MVI 
with minerals supplements daily).23  However, the dosage of supplements can vary greatly which 
could affect serum levels of the nutrient.  MVI and MVI with minerals supplements can range 
from providing very little or no dosage of a nutrient to providing an amount that exceeds the 
DRI’s Tolerable Upper Intake Levels.  Table 44 provides examples of MVI with minerals 
supplements and the variation in folic acid and iron provided. 
 
Table 44:  Folic acid and iron content of various MVI with minerals supplements 
Brand Name of Supplement  
(Manufacturer directions and serving size) 
Folic Acid Iron 
Centrum Chewables, Orange Burst115 
(1 tablet, once daily) 
400 µg 8 mg 
Bariatric Advantage Ultra Multi with Iron116 
(3 capsules, once daily) 
800 µg 45 mg 
BariActiv Multivitamin Chewable117 
(2 tablets, once daily) 
800 µg 0 mg 
One A Day Women’s Prenatal118 
(1 tablet, once daily) 
800 µg 28 mg 
Nature’s Plus Exotic Red Super Fruits Adult’s 
Multi-Vitamin Chewable119 
(1 tablet, once daily) 
100 µg 5 mg 
 
 
Another limitation to the study was poor model fit for the multivariable linear regression 
models for change in serum folate and change in serum ferritin.  The adjusted R-squared values 
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are presented in Table 45.  It is possible that undetected confounding (e.g. no data available on 
dietary intake) may have biased the regression results. 
 
Table 45:  Adjusted R-squared values for the multivariable linear regression models 
Model Adjusted R-squared 
Association of bariatric surgery and change in serum folate 0.28 
Factors associated with change in serum folate after RYGB 0.24 
Association of bariatric surgery and change in serum ferritin 0.23 
Factors associated with change in serum ferritin after RYGB 0.29 
 
 
Finally, for practical reasons, serum folate was used to determine folate status rather than 
RBC folate concentration.  Serum folate level is an indicator of short-term folate status and is 
affected by recent dietary intake.51,55  The RBC folate test is an indicator of longer-term tissue 
folate status.51-53  It is likely that the use of MVI supplements containing folic acid and folate 
supplements increased the serum folate values, and perhaps, was responsible for the large 
proportion of subjects having serum levels above the normal range.  It is also possible that there 
may have been cases of folate deficiency that were not identified due to elevated serum folate 
levels based on recent dietary or supplemental intake of folate/folic acid. 
5.4 STUDY STRENGTHS  
The study had a number of strengths.   This study was conducted as an ancillary study to the 
LABS study which was a multicenter study.  Subjects for the study were selected from ten 
clinical centers in different geographic areas of the U.S., which increased the generalizability of 
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the study.  The researchers had access to a large amount of data that had been collected by 
LABS-trained personnel which were used as variables for the study.  Descriptive data on these 
variables were reported, adding to the body of knowledge produced from the LABS studies (i.e. 
prevalence of folate and iron deficiencies among women of childbearing age and reported 
micronutrient supplement use).  The study also had a larger sample size (n=413 for the folate 
analyses and n=426 for the ferritin analyses) compared to prior studies discussed in the literature 
review.  Unlike many of the prior studies, the current study examined the association of bariatric 
surgery and a number of covariates on the change in serum folate and change in serum ferritin.  
Finally, there was good model fit (c-statistic: 0.73) for the multivariable logistic regression 
model which determined the association of bariatric surgery and ferritin deficiency.   
5.5 PUBLIC HEALTH SIGNIFICANCE 
This research is relevant to public health because of the need for proper nutrition in pregnant 
women.  This study provides evidence that bariatric surgery, RYGB in particular, presents a 
potential risk to perinatal health due to iron deficiency for women who become pregnant at one 
year after surgery.  One year after RYGB, 21.8% of women were deficient in iron.  Maternal 
anemia during pregnancy is associated with a greater risk of preterm birth71-73, low birth weight 
for the infant71, and difficulties with learning, language skills, emotional development, and motor 
skills during childhood74,75.  The results of this research contribute to the body of knowledge 
related to the Healthy People 2020 goal to “improve the health and well-being of women, 
infants, children, and families”.120  In the U.S., 9.6% of infants are born preterm and 8.1% are 
born with low birth weight.121  Based on the results of this research, all women should be tested 
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for iron deficiency one year after RYGB.  This is in agreement with the American Society for 
Metabolic and Bariatric Surgery recommendation that starting at twelve months after bariatric 
surgery iron status should be monitored annually.28  The Committee on Obstetric Practice of the 
American College of Obstetricians and Gynecologists also recommends that women who have 
undergone bariatric surgery and are pregnant, or are planning to become pregnant, should be 
evaluated for potential iron deficiency.40    There is evidence to support delaying pregnancy by at 
least two years after bariatric surgery.  Parent et al.12 reported higher risk of infant prematurity, 
neonatal intensive care admission, and small for gestational age status for women who gave birth 
less than two years after surgery compared to women who gave birth greater than four years after 
bariatric surgery.  
5.6 DIRECTIONS FOR FUTURE RESEARCH 
Based on the outcomes and limitations of this study, a number of recommendations can be made 
for future research directions.  The first recommendation would be to conduct future studies using 
RBC folate concentration as the diagnostic test for folate status rather than serum folate since RBC 
folate test is an indicator of longer-term tissue folate status and would be less affected by recent 
intake of supplements containing folate and dietary intake.51-53.  Second, continued investigation 
of the prevalence of iron deficiency after RYGB is suggested including time points farther out 
from surgery to determine if iron deficiency continues to be a concern at 18 months, two years, 
etc.  These data would be valuable to determine if the current recommendations for the duration of 
time women should wait to become pregnant after RYGB should be revised.   
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In addition, it is advisable that future researchers collect more detailed data on 
micronutrient supplement usage including the dosage of folate and iron in individual 
supplements and MVI or MVI with minerals supplements, how often supplements are taken in a 
day, and the brand name of supplements.  Due to the low percentage of variance explained by the 
multivariable linear regression models investigating the association of bariatric surgery with 
changes in serum ferritin and folate, respectively, researchers should consider other factors not 
included in the study that may have an association such as dietary intake.  Finally, a similar study 
should be conducted with women of childbearing age who have undergone sleeve gastrectomy, 
which is currently performed more commonly than LAGB1. 
5.7 CONCLUSION 
The primary goals of this study were to: 1) investigate the association of two types of bariatric 
surgery, LAGB and RYGB, with change in serum folate and change in serum ferritin from prior 
to surgery to one year following surgery among women of childbearing age; 2) determine factors 
associated with change in serum folate and change in serum ferritin after RYGB; and 3) 
determine the prevalence of folate and iron deficiency one year after surgery.  The results 
showed that type of surgery was not significantly associated with change in serum folate, after 
adjusting for other covariates, but this may have been a function of the limitations in the assay 
which reflects short-term folate status and can be affected by recent intake.  Hence, additional 
research is recommended using RBC folate concentration instead of serum folate to determine 
folate status.  The results of this research indicate that, despite the positive effect of multivitamin 
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with minerals supplement use, iron deficiency is a concern at one year after RYGB and 
monitoring for iron deficiency one year after surgery is recommended for all women.    
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